3URGXFW$0*
3URWRFRO1XPEHU
'DWH0DUFK 3DJHRI
&21),'(17,$/7LWOH$Q2SHQODEHO([WHQVLRQ2/(6WXG\WR$VVHVVWKH/RQJ WHUP6DIHW\DQG
(IILFDF\RI$0*
$PJHQ3URWRFRO1XPEHU$0*
(XGUD&7QXPEHU  
&OLQLFDO6WXG\6SRQVRU $PJHQ,QF
2QH$PJHQ&HQWHU'ULYH7KRXVDQG2DNV&$86$
7HO
.H\6SRQVRU&RQWDFWV
'DWH 'HFHPEHU
6XSHUVHGLQJ'DWH -DQXDU\$PHQGPHQW -DQXDU\ 
$PHQGPHQW 2FWREHU
$PHQGPHQW 0DUFK
&RQILGHQWLDOLW\1RWLFH
7KLVGRFXPHQWFRQWDLQVFRQILGHQWLDOLQIRUPDWLRQRI$PJHQ,QF
7KLVGRFXPHQWPXVWQRWEHGLVFORVHGWRDQ\RQHRWKHUWKDQWKHVL WHVWXG\VWDIIDQG
PHPEHUVRIWKHLQVWLWXWLRQDO UHYLHZERDUGLQGHSHQGHQWHWKLFVFR PPLWWHHLQVWLWXWLRQDO
VFLHQWLILFUHYLHZERDUGRUHTXLYDOHQW
7KHLQIRUPDWLRQLQWKLVGRFX PHQWFDQQRWEHXVHGIRUDQ\SXUSRVH RWKHUWKDQWKH
HYDOXDWLRQRUFRQGXFWRIWKHFOLQLFDOLQYHVWLJDWLRQZLWKRXWWKH SULRUZULWWHQFRQVHQWRI
$PJHQ,QF 
,I\RXKDYHTXHVWLRQVUHJDUGL QJKRZWKLVGRFXPHQWPD\EHXVHGR UVKDUHGFDOOWKH
$PJHQ0HGLFDO,QIRUPDWLRQQXPEHU86VLWHV$0*(1& DQDGLDQVLWHV
$0*(1IRUDOORWKHUFRXQWULHV
1&71XPEHU
7KLV1&7QXPEHUKDVEHHQDSSOLHGWRWKHGRFXPHQW
IRUSXUSRVHVRISRVWLQJRQFOLQLFDOWULDOVJRY[COMPANY_003]
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE] 
Date:  31 March  2016  Page 2 of 84 
CONFIDENTIAL    Investigator‚Äôs Agreement  
I have read the attached protocol entitled An Open-label Extension (OLE) Study to 
Assess the Long-term Safety and Efficacy of AMG 334, dated 31 March 2016, and 
agree to abide by [CONTACT_3769].    
I agree to comply with the International Conference on Harmonisation (ICH) Tripartite 
Guideline on Good Clinical Practice  (GCP) and applicable national or regional 
regulations/guidelines .  
I agree to ensure that Financial Disclosure Statements will be completed by: 
‚Ä¢ me (including, if applicable, my spouse [or legal partner] and dependent children)  
‚Ä¢ my subinvestigators (including, if applicable, their spouses [or legal partners] and 
dependent children)  
at the start of the study and for up to one year after the study is completed, if there are 
changes that affect my financial disclosure status. 
I agree to ensure that the confidential information contained in this document will not be 
used for any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written consent of [COMPANY_010] Inc.  
   
Signature   
[CONTACT_21989] (DD Month YYYY)  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE] 
Date:  31 March  2016  Page 3 of 84 
CONFIDENTIAL    Protocol Synopsis 
Title:   An Open- label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of 
AMG 334  
Study Phase:  Open -label extension  
Indication:   Prevention of chronic migraine  
Primary Objective:   To characterize  the safety and tolerability of long- term administration of 
AMG  334    
‚Ä¢ Primary Objective of Clinical Home Use (CHU)  Substudy:   To assess users‚Äô ability to 
administer a full dose of AMG 334 in home- use, using eith er two prefilled syringe s (PFS) or 
two prefilled autoinjector /pens (AI/pen). 
Secondary Objectives:    
‚Ä¢ To characterize  the efficacy of long- term administration of AMG 334 as assessed by:  
‚Ä¢ Change from baseline in monthly migraine days  
‚Ä¢ Proportion of subjects with at least 50% reduction from baseline in monthly migraine days  
‚Ä¢ Change from baseline in monthly acute migraine- specific medication treatment days  
‚Ä¢ Change from baseline in monthly cumulative hours of headache  
‚Ä¢ Secondary  Objective of CHU Substudy:   To assess  the safety and toler ability of AMG  334 
administered using two 1- mL PFS or two 1 -mL AI/pen s 
For the purpose of primary  analysis for secondary and exploratory endpoints in the 20130255 
open -label extension (OLE) study, baseline is defined as baseline of the AMG 334 20120295 
parent study (from the first day subject used eDiary in baseline at week -4 study visit through the 
day prior to study day 1).   However, change from week 8 through 12 data of the parent study  
(hereafter referred to as parent study Month 3 data) will also be evaluated.  
Hypotheses:   The clinical hypothesis is that long- term exposure of AMG 334 will be safe and 
well tolerated in subjects with chronic migraine 
Primary Endpoint:   Subject incidence of adverse events  
Secondary Endpoints: 
‚Ä¢ Change f rom baseline in monthly migraine days at assessment timepoints  
‚Ä¢ Achievement of  at least a 50% reduction from baseline in monthly migraine days at 
assessment timepoints  
‚Ä¢ Change from baseline in monthly migraine- specific medication treatment days at assessment  
timepoints  
‚Ä¢ Change from baseline in cumulative monthly headache hours at assessment timepoints  
Study Design:   This is a multicenter, open- label study designed to assess the long- term safety 
and efficacy of AMG 334.  Subjects who complete the 12- week double- blind treatment phase of 
the AMG [ADDRESS_32516] not yet enroll ed in the study will receive open- label AMG 334 140 mg every 
month ( QM) subcutaneous ( SC) for [ADDRESS_32517]:  AMG 334  
Protocol Number:  201 [ZIP_CODE] 
Date:  [ADDRESS_32518] the option 
to decrease open- label AMG 334 from 140 mg QM to 70 mg QM.  The 13- month open -label 
AMG  334 treatment phase will be followed by a 12- week safety follow -up visit ([ADDRESS_32519]).    
Sample Size:   All subjects who completed the 12-week double -blind treatment phase of the 
AMG  [ADDRESS_32520] Eligibility  Criteria:   Adults with  history of chronic migraine and who 
completed the 12-week double- blind treatment phase  of the parent study .  For a full list of 
eligibility criteria, please refer to Section 4.1.  
[COMPANY_010] Investigational Product Dosage and Administration:   Investigational product (IP) 
(ie, AMG 334 70 mg or 140 mg) will  be dosed QM by [CONTACT_10530].   For subjects participating in 
the CHU substudy, IP is AMG  334 140 mg in either a PFS or prefilled AI/Pen . 
Procedures:   Prior to enrolling in this study, subjects will need to undergo week-[ADDRESS_32521] iogram 
(ECG ) central reader report.  Subject  numbers will be the same as those in the parent study.   
After signing informed  consent, subjects will have monthly in -clinic study visits throughout the 
13-month treatment phase.  During these visits, IP will be administered and study -related 
procedures will be completed.   
All subjects will receive open -label AMG 334 QM SC for 13 months  followed by a 12- week  safety 
follow up visit ([ADDRESS_32522] dose of IP).  
Subjects will use an electronic diary (eDiary) every day between the Day [ADDRESS_32523] of study  procedures, including the timing of each procedure, please refer to 
Section  7 and the Schedule of Assessments  (Table  1).   
Statistical Considerati ons:   
For the purpose of primary analysis for secondary and exploratory endpoints in the 20130255 
OLE study, baseline is defined as baseline of the AMG 334 20120295 parent study (from the first day subject used eDiary in baseline at week - 4 study visit th rough the day prior to study day 1).   
However, change from parent study Month [ADDRESS_32524] will be 
provided.     
For a full description of statistical  analysis methods, please refer to Section 10. 
Sponsor :  [COMPANY_010] Inc.  
Data Element Standards Version/Date:  Version 4 .0 ‚Äì 01 November  2013  
 


 3URGXFW$0*
3URWRFRO1XPEHU'DWH0DUFK 3DJHRI
&21),'(17,$/ 6WXG\'HVLJQDQG7UHDWPHQW6FKHPD






 3URGXFW$0*
3URWRFRO1XPEHU'DWH0DUFK 3DJHRI
&21),'(17,$/ 

 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 7 of 84 
CONFIDEN TIAL    Study Glossary  
Abbreviation or Term  Definition/Explanation  
ADL Activities of daily living  
ADE Adverse Device Effects  
AE Adverse event  
AI/pen Autoinjector /pen 
ALP Alkaline phosphatase  
ALT Alanine aminotransferase  
AST Aspartate aminotransferase 
AUC  Area under the curve  
Baseline  For the purpose of primary analysis for secondary and exploratory 
endpoints in the 20130255 OLE study, baseline is defined as baseline of the AMG 334 20120295 parent study (from the first day  
subject used eDiary in baseline at week -4 study visit through the 
day prior to study day 1).    
Change from week 8 through 12 data of the parent study  (referred to 
as parent study Month 3 data) will also be evaluated.  
BIL Bilirubin  
BP Blood pressure  
BUN Blood urea nitrogen  
CBC  Complete blood count  
CGRP  Calcitonin gene- related peptide  
CHU  Clinical Home Use  
Cmax Peak concentration  
COAs  Clinical Outcomes Assessments  
Combination -analgesic  combination formulations of simple analgesics with opi[INVESTIGATOR_33166]  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CTCAE    Common Terminology Criteria for Adverse Events  
Day 1 / Study Day [ADDRESS_32525]  
DBF Dermal blood flow  
DILI Drug -induced liver injury  
EC 90 90% effective concentration 
ECG  Electrocardiogram  
EDC  Electronic data capture  
eCRF  Electronic case report form  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 8 of 84 
CONFIDEN TIAL    Abbreviation or Term  Definition/Explanation  
eDiary(ies)  Electronic diary(ies)  
End of study for indiv idual 
subject  The last day at which protocol -specified procedures are conducted 
for an individual subject . 
End of Trial  The time when the last subject is assessed for evaluation in the 
study (ie, when the last subject completes the study, which includes the safety follow -
up visit after the last dose of investigational product, 
or is discontinued from the study).  
Enrollment  Timepoint at which a subject meets all screening  eligibility criteria 
and enrolls into the baseline phase of the study .   
ET Early te rmination  
ETO System  Electronic Trial Operations System; an electronic system that is used 
to facilitate the operations of a clinical trial through the collection of study -related data.  The most common applications of an ETO 
system within a clinical tria l are subject randomization and 
investigational product management.  The term is synonymous with the industry term Interactive Voice Response (IVR) / Interactive Web Response (IWR) System.   
FAS Full analysis set  
FDA Food and Drug Administration  
FSH Follicle-stimulating hormone 
HDL High-density lipoprotein  
Headache  A migraine or non- migraine headache  
Headache Day  Any calendar day in which the subject experiences a qualified migraine or non- migraine headache (initial onset, continuation or 
recurrence of the headache)  lasting ‚â• 4 continuous hours, or a 
headache of any duration for which acute medication (simple 
analgesics, combination analgesics, triptans, ergot -derivatives, 
opi[INVESTIGATOR_858])  was administered for treatment of headache pain.  
Headache Day with moderate or severe 
intensity  Any calendar day in which the subject experiences a headache,  with headache pain last ing ‚â• [ADDRESS_32526] (ie, AMG  334 or if participating in CHU 
substudy, AMG 334 in either a PFS or prefilled AI/Pen ) 
IPIM Investigational Product Instructional Manual  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 9 of 84 
CONFIDEN TIAL    Abbreviation or Term  Definition/Explanation  
IRB Institutional Review Board  
IVR/IWR System  Interactive Voice Response (IVR) / Interactive Web Response (IWR) 
System; telecommunication / internet technology that is linked to a central computer in real time as an interface to collect and process information . 
Kd The equilibrium dissociation constant  
LDH Lactate dehydrogenase  
LDL Low-density lipoprotein  
M Month  
MCH  Mean corpuscular hemoglobin  
MCHC  Mean corpuscular hemoglobin concentration  
MCV  Mean corpuscular volume  
MIDAS Migraine Disability Assessment  
Migraine Attack  An epi[INVESTIGATOR_33167] a triptan or ergot- derivative to treat headache or 
aura.  The following rules will be used for distinguishing an attack of long duration from two attacks, or for distinguishing between attacks and relapses:  
a) A migraine attack which is interrupted by [CONTACT_33222], and then recurs within 48 hours after onset of the attack will be considered as one attack, and not two.  
b) An attack primarily treated successfully with medication but with relapse within [ADDRESS_32527]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 10 of 84 
CONFIDEN TIAL    Abbreviation or Term  Definition/Explanation  
Migraine Day  Any calendar day in which the subject experiences a qualified 
migraine headache (onset, continuation, or recurrence of the migraine headache).  A qualified migraine headache is defined either as a migraine without aura or a migraine with aura as outlined below:  
1. A migraine without aura, lasting for ‚â• 4 continuous hours, and 
meeting criteria a and/or b:  
a) ‚â• 2 of the following pain features:   
‚Ä¢ Unilateral  
‚Ä¢ Throbbing  
‚Ä¢ Moderate to severe  
‚Ä¢ Exacerbated with  exercise/physical activity  
b) ‚â• 1 of the associated symptoms:   
‚Ä¢ Nausea  and/or vomiting  
‚Ä¢ Photophobia and phonophobia  
OR 
2. A migraine with aura and meeting criteria a and b:  
a) Meeting ‚â• 1 of the following fully reversible aura symptoms:  
‚Ä¢ Visual  
‚Ä¢ Sensory  
‚Ä¢ Speech and/or language  
‚Ä¢ Retinal  
‚Ä¢ Brainstem  
b) Aura is accompanied, or followed within 60 minutes, by 
[CONTACT_33223] ‚â• [ADDRESS_32528] took a triptan or ergot -derivative on a calendar day, 
then it will be counted as a migraine day regardless of the duration and pain features/associated symptoms.  
Monthly Headache Days Number of headache days in any 28- consecutive day interval 
relative to study day 1.   
Monthly Migraine Days  Number of migraine days in any 28- consecutive day interval relative 
to study day 1.   
MPFID  Migraine Physical Function Impact Diary  
MSQ  Migrai ne-specific Quality of Life Questionnaire  
MWt molecular weight  
NOAEL  No observed adverse effect level  
OLE Open -label extension  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 11 of 84 
CONFIDEN TIAL    Abbreviation or Term  Definition/Explanation  
Parent study  AMG [ADDRESS_32529] is assessed for evaluation in the study (ie, when the last subject completes the study, which includes the safety follow -
up visit after the last dose of investigational product, 
or is discontinued from the study).  
PRO  Patient -reported outcome  
PROMIS  Patient Reported Outcomes Measurement Information System Pain Interference Scale short form  
QM Every month / Monthly  
RBC  Red blood cell  
RDW Red blood cell distribution width  
RG Reference Guide  
SAE Seriou s adverse event  
SAS Safety analysis set  
SC Subcutaneous  
SEC Self-evident corrections  
SGOT  serum glutamic -oxaloacetic transaminase; see AST  
SGPT  serum glutamic -pyruvic transaminase; see ALT  
Simple analgesic  Includes non- narcotic analgesics such as acetaminophen or NSAIDs  
Source Data  Information from an original record or certified copy of the original record containing patient information for use in clinical research.   
The information may include, but is not limited to, clinical findings, observations , or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial.  Source data are contained in source documents (original records or certified copi[INVESTIGATOR_014]) (ICH Guideline E6).  Examples of source data include subject ident ification and randomization identification. 
TBL Total bilirubin  
tmax time to peak concentration  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 12 of 84 
CONFIDEN TIAL    Abbreviation or Term  Definition/Explanation  
True abstinence  To refrain from any sort of sexual activity that could involve the spi[INVESTIGATOR_33168], even if the spi[INVESTIGATOR_33169] . 
TSH Thyroid -stimulating hormone 
ULN Upper limit of normal  
WBC  White blood cell 
Wk Week  
WOCBP  Woman/women of childbearing potential; any female who has experienced menarche and does not meet the criteria for ‚ÄúWomen not of childbearing potential‚Äù  
Women not Any female who:  of 
childbear ing potential  ‚Ä¢ Is post -menopausal by [CONTACT_33224]  
o Age ‚â• 55 years with cessation of  menses for 12 or 
more months, OR   
o Age < [ADDRESS_32530] 2 years, OR   
o Age < [ADDRESS_32531] 1 year , but currently amenorrheic (eg, 
spontaneous or secondary to hysterectomy), AND with postmenopausal gonadotropin levels (luteinizing hormone and follicle -stimulating 
hormone levels > 40 IU/L) or postmenopausal 
estradiol levels (< 5 ng/dL) or according to the definition of "postmenopausal range" for the 
laboratory involved.  
OR 
‚Ä¢ Underwent bilateral oophorectomy  OR 
‚Ä¢ Underwent hysterectomy  OR 
‚Ä¢ Underwent bilateral  salpi[INVESTIGATOR_1656] . 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32532] - AMG 334  ................................ 29 
[IP_ADDRESS] Dosage, Adm i
nistration, and Schedule .................... 29 
[IP_ADDRESS] Rules for Withholding or Restarting 
Investigational Product  ............................................. [ADDRESS_32533]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32534] Complaints  .................................................................................... 34 
7. STUD Y PR OCEDURES  ......................................................................................... 34 
7.1 Schedule of Assessments  .......................................................................... 34 
7.2 General Study Procedures  ......................................................................... 40 
7.2.1 Study Specific Assessments ...................................................... 40 
[IP_ADDRESS] Informed Consent  .................................................... 40 
[IP_ADDRESS] Calls to Interactive Voice Response (IVR) / 
Interactive Web Response (IWR) System  ............... 40 
[IP_ADDRESS] Physical Examination ............................................... 40 
[IP_ADDRESS] Weight Measurements  ............................................. 40 
[IP_ADDRESS] Vital Signs  ................................................................ 40 
[IP_ADDRESS] Urine Drug Screening .............................................. 41 
[IP_ADDRESS] Pregnancy Testing for Women of Childbearing Potential  .............................................. 41 
[IP_ADDRESS] Electrocardiogram (ECG)  ......................................... 41 
[IP_ADDRESS] Pharmacokinetic (PK) Sampling .............................. 42 
[IP_ADDRESS] Clinical Outcomes Assessments (COAs) 
and Electronic Diaries (eDiaries)  ............................. 42 
[IP_ADDRESS] Migraine Symptom Interference Items  ..................... 43 
[IP_ADDRESS] Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Scale Short Form  ................................. 43 
[IP_ADDRESS] Migraine-specific Quality of Life 
Questionnaire (MSQ)  ............................................... 43 
[IP_ADDRESS] Migraine Disability Assessment 
Questionnaire (MIDAS) ............................................ 44 
[IP_ADDRESS] Novel PRO Instrument Substudy (Optional)  ................................................................. 44 
[IP_ADDRESS] Clinical Home Use Substudy (Optional; 
Limited to Subjects in US, [LOCATION_013] and 
Sweden)  ................................................................... 45 
[IP_ADDRESS] Columbia-Suicide Severity Rating Scale (C-SSRS) ................................................................. 46 
[IP_ADDRESS] Concomitant Medications Recording  ....................... 47 
[IP_ADDRESS] Adverse Event Reporting ......................................... 47 
[IP_ADDRESS] Laboratory Assessments  ......................................... [ADDRESS_32535]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 15 of 84 
CONFIDEN TIAL    7.2.5 Safety Follow -up ......................................................................... 51 
7.3 Antibody Testing Procedures  ..................................................................... 52 
7.4 Biomarker Development  ............................................................................. 52 
7.5 Sample Storage and Destruction  ................................................................ 53 
8. WITHDRAWAL FROM TREATMENT, PROCEDURES, AND STUDY  .................. 54 
8.1 Subjects‚Äô Decision to Withdraw .................................................................. 54 
8.2 Investigator or Sponsor Decision to Withdraw or Terminate 
Subjects‚Äô Participation Prior to Study Completion ...................................... 55 
8.3 Reasons for Removal From Treatment and Study  ..................................... 55 
8.3.1 Reasons for Removal From Treatment ...................................... 55 
8.3.2 Reasons for Removal From Study  ............................................. 55 
9. SAFETY DATA COLLECTION, RECORDING, AND REPORTING  ....................... 55 
9.1 Adverse Events  .......................................................................................... 55 
9.1.1 Definition of Adverse Events  ...................................................... 55 
9.1.2 Definition of Serious Adverse Events  ......................................... 56 
9.2 Reporting of Adverse Events  ...................................................................... 57 
9.2.1 Reporting Procedures for Adverse Events That do not 
Meet Serious Criteria  .................................................................. 57 
9.2.2 Reporting Procedures for Serious Adverse Events  .................... 58 
9.3 Adverse Event Adjudication ........................................................................ 59 
9.4 Pregnancy and Lactation Reporting ........................................................... 60 
10. STATISTICAL CONSIDERATIONS  ....................................................................... 61 
10.1 Study Endpoints, Analysis Sets, and Covariates  ........................................ 61 
10.1.1 Study Endpoints  ......................................................................... 61 
[IP_ADDRESS] Primary Endpoint ..................................................... 61 
[IP_ADDRESS] Secondary Endpoints  ............................................... 61 
[IP_ADDRESS] Exploratory Endpoints .............................................. 61 
[IP_ADDRESS] Clinical Outcome Assessments  - Definition 
of Terms Included in Endpoints  ............................... [ADDRESS_32536]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32537]/Independent Ethics Committee  ........................ [ADDRESS_32538] of Figures 
Figure 1.  Predicted Capsaicin- induced Dermal Blood Flow (DBF) Inhibition 
(Left) and AMG  334 Exposure (Right) for the Phase [ADDRESS_32539]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 17 of 84 
CONFIDEN TIAL    1. OBJECTIVES  
1.1 Primary 
To characterize the safety and tolerability of long -term administration of AMG 334  
‚Ä¢ Primary Objective of Clinical Home Use (CHU) Substudy:  To assess users‚Äô ability to 
administer a full dose of AMG 334 in home-use, using either two prefilled syringes 
(PFS) or two prefilled autoinjector /pens (AI /pen) 
1.2 Secondary  
To characterize the efficacy of long-term administration of AMG 334 as assessed by: 
‚Ä¢ Change from baseline in monthly migraine days  
‚Ä¢ Proportion of subjects with at least 50% reduction from baseline in monthly migraine 
days  
‚Ä¢ Change from baseline in monthly acute migraine-specific medication treatment days    
‚Ä¢ Change from baseline in  monthly cumulative hours of headache   
For the purpose of primary analysis for secondary and exploratory endpoints in the 
20130255 open-label extension ( OLE) study, baseline is defined as baseline of the 
AMG 334 20120295 parent study (from the first day subject used eDiary in baseline at 
week -4 study visit through the day prior to study day 1).  However, change from week 8 
through 12 data of the parent study (hereafter referred to as parent study Month 3 data) 
will also be evaluated. 
‚Ä¢ Secondary  Objective of CHU Substudy:  To assess the safety and tolerability of 
AMG 334 administered using two 1- mL PFS or two 1-mL AI /pens 
1.3 Exploratory 
‚Ä¢ To evaluate the effect of AMG 334 as measured by [CONTACT_33225], in subjects with chronic migraine  
‚Ä¢ To evaluate the effect of AMG 334 as measured by [CONTACT_33226] (migraine and non-migraine headache) days , headache days with 
moderate or severe intensity , monthly average severity of migraine pain  
‚Ä¢ To evaluate the effect of AMG 334 as measured by [CONTACT_33227] (nausea, vomiting, 
phonophobia, photophobia) for qualified migraine headaches   
‚Ä¢ To evaluate the effect of AMG 334 on migraine-specific quality of life (as measur ed 
by [CONTACT_33228]-Specific Quality of Life Questionnaire [ MSQ], version 2.1), 
migraine-related disability (as measured by [CONTACT_33229] 
[MIDAS ]), pain interference with daily activities and migraine-specific impact (as 
measured by [CONTACT_33230]-Reported Outcomes Measurement Information System 
[PROMIS ] Pain Interference Scale short form and single pain and migraine symptom 
interference questions ) 
‚Ä¢ To evaluate effect of AMG [ADDRESS_32540] Diary (MPFID)  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 18 of 84 
CONFIDEN TIAL    ‚Ä¢ To evaluate the effect of AMG [ADDRESS_32541] on everyday activities  over 
time as measured by [CONTACT_33231]  
‚Ä¢ To evaluate AMG 334 pharmacokinetic (PK) in subjects with migraine    
‚Ä¢ To investigate potential biomarker development by [CONTACT_33232]  
2. BACKGROUND AND RATIONALE  
2.[ADDRESS_32542] two of the following pain characteristics:  
unilateral, pulsating, moderate or  severe intensity, or aggravated by [CONTACT_33233].  In addition, the migraine attacks are often accompanied by [CONTACT_33234], vomiting, 
and sensitivity to light (photophobia) and sound (phonophobia).  The pathophysiology of 
aura may differ from that of migraine pain (Eikermann-Haerter and Ayata, 2010).  Migraine is a highly prevalent disease worldwide.  The prevalence of migraine is  
approximately 11.7% in the [LOCATION_003], 14.6% in Canada, and 14.7% in Europe 
(Lipton et al, 2007; Stovner and Andree, 2010).   The disease is more common in women 
than in men and presents most often during the period of an individual‚Äôs peak economic 
productivity between the ages of 30 and 50 years  of age (Lipton et al, 2007; 
Stovner et al, 2007; Stovner and Andree, 2010).  Depending on the headache 
frequency, migraine is divided into two broad forms:  epi[INVESTIGATOR_33170] [ICHD-3 ].  Epi[INVESTIGATOR_33171] 
15 headache days per month, while chronic  migraine is characterized by 15 or more 
headache days per month (where at least 8 of those days are migraine days) .  Epi[INVESTIGATOR_33172], 
which include the headache pain features and associated symptoms.  However, there 
are also differences between patients with epi[INVESTIGATOR_33173], r isk factors and co-morbidities.  In general, patients with 
chronic  migraine experience more severe and disabling migraine attacks , and have 
more co-morbidities (eg, depression and anxiety, chronic pain and cardiovascular disorders ) than patients with epi[INVESTIGATOR_17730].  Individuals with chronic migraine are 
typi[INVESTIGATOR_33174], have lower  levels of overall education, lower household incomes and are 
less likely to be working full time than individuals diagnosed with epi[INVESTIGATOR_33175] (Diener et al, 2012; Katsarava et al, 2012).   
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32543] frequently used acute 
migraine medications include analgesics and a class of drugs called triptans ( Houston 
and Vanhoutte, 1986; Humphrey et al, 1990).  I t has been demonstrated the triptans are 
effective in both epi[INVESTIGATOR_33176], although those with chronic migraine  
tend to have less robust response to tr iptans than those with epi[INVESTIGATOR_17730] (Lipton 
and Chu, 2009).  Based on published treatment guidelines , up to 40% of the migraine 
patient population (including all patients with chronic migr aine) would benefit from 
preventive therapy ( Lipton et al, 2001).  The available migraine preventive therapi[INVESTIGATOR_33177].  Migraine 
prophylaxis is an area of large unmet medical need.  While recommendations exist for 
the preventive treatment of migraine headache in the U.S. and Europe, most of the medications were evaluated in epi[INVESTIGATOR_17730] (Silberstein et al, 2012; Evers et al, 
2009).  Topi[INVESTIGATOR_33178]-controlled trials 
(Diener et al, 2007; Silberstein et al, 2007).  However, topi[INVESTIGATOR_33179], anorexia, psychomotor slowing, 
somnolence, language difficulties, and difficulties with memory and concentration 
(Adelman et al, 2008; Brandes et al, 2004).   Additionally, onabotulinumtoxinA was 
recently approved by U nited States  Food and D rug Admi nistration (FDA), several  EU 
countries , and Canada for prophylaxis of chronic migraine, based on 2 randomized, 
placebo-controlled, double-blind studies (Aurora et al, 2010; Diener et al, 2010).     
Calcitonin Gene-related Peptide (CGRP)  
Migraine was historically considered to be due to vasodilatation of cranial blood vessels.  More recent understanding of the pathophysiology of migraine indicates that the vasodilatation of the cranial blood vessels is secondary to activation of the trigeminal 
nociceptive pathway ( Goadsby [CONTACT_2297], 2002).  CGRP is a 37 amino acid peptide 
expressed in both the central and peripheral nervous systems including the trigeminal 
ganglion and nucleus, and is believed to be a key mediator of migraine based on several lines of evidence.  CGRP was elevated in jugular venous blood  in migraine attacks  
(Goadsby [CONTACT_2297], 1990) and was also elevated interictal ly in migraine patients ( Ashina et 
al, 2000), and trials with antagonists to the CGRP receptor demonstrated efficacy in acute migraine with aura and migraine without aura (Connor et al 2009; Ho et al , 2008 ; 
Ho et al, 2010; Olesen et al, 2004).  It is expected that mechanistically antagonism of the 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32544] could be a potentially effective treatment for prophylaxis of epi[INVESTIGATOR_33180]. 
2.2 AMG 334 Background 
AMG 334 is a human monoclonal immunoglobulin (IgG2) against the CGRP receptor.  
AMG 334 binds to the CGRP receptor complex with high affinity (K d of 20 pM) and 
competitively and reversibly blocks the binding of the native ligand, CGRP.  AMG [ADDRESS_32545].   
The potential mechanisms of action of CGRP receptor antagonists involve components of the trigeminal -vascular system and include normalization of CGRP -induced 
vasodilation, reduction of C GRP -induced neurogenic inflammation, and inhibition of pain 
transmission at the trigeminal ganglion and trigeminal nucleus (Durham, 2004; Poyner, 1992; Wang et al, 1995; Zimmermann et al, 1996 ).  The site of action for AMG 334 will 
be predominantly restricted to the periphery due to AMG 334‚Äôs physical size and 
structure (antibody).  While it is not definitively  known whether the CGRP receptors that 
are relevant for migraine lie within or outside of the blood brain barrier, t he following 
scientific evidence argues strongly for a predominant role for peripheral CGRP in the generation of migraine: 
1) CGRP -induced migraine headaches via intravenous (IV) infusion are most 
likely initiated through peripheral CGRP receptor signaling systems . 
a. Migraine can be initiated by [CONTACT_33235] ( Lassen et al , 2002). 
b. CGRP is a 37-amino acid peptide (molecular weight [MWt ] 
>3700 daltons).  It most likely has limited brain penetration across the 
blood brain barrier  (MWt cut off for brain penetration is ~ 500 daltons) . 
c. CGRP peptide has a short plasma half -life [mean plasma 
T
¬Ω~11 min in man ( Kraenzlin et al , 1985)] .   
2) The physical and chemical properties of the CGRP -receptor antagonists 
olcegepant and telcagepant suggest that their site of action is likely to be in 
the periphery . 
a. Olcegepant is a peptidic IV CGRP-receptor antagonist that has a 
molecular weight (MWt 870 daltons)   that is greater than the upper 
limit for blood brain barrier penetration with low oral bioavailabili ty 
(Rudolf et al , 2005).  
b. A positron emission tomography (PET) study showed minimal  brain 
penetration of telcagepant and low central receptor occupancy (4-10%) at the clinically efficacious dose of 140 mg (Connor et al, 
2009; Ho et al, 2010; Hostetler et al, 2013 ).  This degree of receptor 
occupancy would be unlikely to produce a functional effect.  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32546] was saturated at a lower dose of 150 mg, which has 
little to no evidence of brain receptor occupancy  (Connor et al, 2009). 
3) Antagonist mechanisms typi[INVESTIGATOR_33181] 
(>60%) to produce a p harmacodynamic  (PD) effect resulting in efficacy 
(Grimwood and Hartig, 2009). 
Given the likely peripheral activity of AMG [ADDRESS_32547] the treatment of aura, which is considered a central phenomenon (Eikermann-Haerter et al, 2012).   
The preclinical toxicology data were generated in cynomolgus monkey as it is  the only 
laboratory species in which AMG  [ADDRESS_32548] level (NOAEL) was the maximum  dose 
evaluated in the 6-month Good Laboratory Practice (GLP) toxicology study, 
150 mg/kg subcutaneous (SC).  There were no significant effects on electrocardiogram  
(ECG ) parameters, blood pressur e (BP) or respi[INVESTIGATOR_33182].  
The safety and PK of AMG [ADDRESS_32549]-in -human 
study .  AMG 334 exposure increased more than dose proportionally at doses from  
1 to 70 mg SC and increased approximately dose proportionally from 70 to 210 mg  SC 
in healthy subjects.  The median time of maximum observed concentration (t
max) ranged 
from [ADDRESS_32550] cohorts and the migraineur cohort. 
In preliminary  PK results from healthy subjects in the multiple -dose study, t he observed 
mean area under the curve ( AUC) 0-28d accumulation ratio at all 3 dose levels  (21, 70, and 
140 mg) after 3 monthly SC administrations  was < 2, which  is consistent with the dosing 
frequency and half-life of monoclonal antibodies .  
Refer to the AMG 334 Investigator‚Äôs Brochure for additional information. 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 22 of 84 
CONFIDEN TIAL    2.3 Rationale 
Migraine prophylaxis  in chronic migraine is an area of large unmet medical need, with 
existing therapi[INVESTIGATOR_33183].  While a variety of medications 
are used off -label for prophylaxis of chronic migraine, only onabotulinumtoxinA  is 
approved for this indication.  CGRP receptor antagonism represents a novel approach to 
migraine therapi[INVESTIGATOR_014].  Results from the AMG 334 p hase 2 study (Study 20120178) in 
subjects with epi[INVESTIGATOR_33184] 70 mg dose resulted in 
statistically significant and clinically meaningful reductions in monthly migraine days at 
week 12 compared with placebo (70 mg: -3.40 vs Placebo: -2.28; Difference: -1.12; 
p = 0.02).  Neither the 7 mg nor the 21 mg dose was associated with statistically 
significant reductions in monthly migraine days.  The 70 mg dose produced statistically 
significant improvements in multiple secondary and exploratory outcome measures, including the 50% responder rate, monthly headache days, and monthly migraine-specific medication treatment days, while neither the [ADDRESS_32551] dose that results in efficacious 
concentrations  (Lenz  et al, 2015; Sun et al, 2015 ).  This study is designed to assess 
whether a CGRP receptor antagonist is  safe and well tolerated in subjects with chronic 
migraine.   
Rationale for AMG  [ADDRESS_32552] been generally well tolerated in 
phase 1 studies and that this dose is predicted to  result in near complete inhibition of the 
peripheral CGRP receptor for a month.  To ensure optimal efficacy is achieved with 
AMG 334, a higher dose, 140 mg, is currently being evaluated in the double-blind 
placebo-controlled parent study in chronic migraine (Study 20120295) as well as in a phase 3 study in Epi[INVESTIGATOR_33185] (Study 20120296) and efficacy data are being 
collected.  Based on the AMG [ADDRESS_32553] level from preclinical toxicology studies was determined 
to be the high dose, 150 mg/kg SC twice weekly, corresponding to a maximum 
concentration (C
max) of 2620 Œºg/mL, and AUC 0-7d of [ZIP_CODE] Œºg‚Ä¢day/mL.  This is 275-fold 
and 296-fold higher than the observed mean C max and AUC 0-28d,  in humans after the third  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32554] monthly subcutaneous  
administration in humans of 140 mg, after  corre cting the different dosing frequency in 
cynomolgus monkeys and humans . 
Based on the clinical data generated to date, it is expected that multiple doses of 
AMG 334 up to 140 mg will be well tolerated in subjects with migraine.  AMG 334 has 
been administered at single doses up to 210 mg SC and 140 mg IV and at doses up to 
140 mg SC administered monthly for 3 months  in migraine subjects, and in healthy 
subjects at doses of 280 mg SC administered on day 1 followed by 210 mg SC administered on days 29 and 57.  R efer to the AMG 334 Investigator‚Äôs Brochure for 
details.   
The ability of AMG 334 to inhibit CGRP receptor s in humans was evaluated by [CONTACT_33236][INVESTIGATOR_33186].  This capsaicin- induced 
DBF model has been used to demonstrate proof of pharmacological activity for CGRP antagonists (eg, telcagepant, olcegepant)  (Sinclair et al, 2010).  Based on the results of 
the study with AMG 334, a dose of 70 mg is predicted to result in near complete 
inhibition of the peripheral CGRP receptor for a month.  The plasma concentration 
achieved at 70 mg i s approximately 10 fold higher than the 90% effective concentration 
(EC
90) from the DBF model and is sustained for greater than 28 days ( Figure 1 ).  The 
correlation between the DBF model and clinical efficacy in migraine prophylaxis has not been established with AMG 334 although clinical efficacy has been demonstrated in 
acute migraine treatment for telcagepant (a small molecule CGRP antagonist) at doses with concentrations approximately 2 - 4 fold higher than EC
90 from the DBF model 
studies ( Connor et al, 2009; Ho et al, 2008; Sinclair et al, 2010).  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 24 of 84 
CONFIDEN TIAL    Figure 1 .  Predicted Capsaicin-induced Dermal Blood Flow (DBF) Inhibition (Left) 
and AMG  334 Exposure (Right) for the Phase 2 Doses  
 
Figure legends:  Lines in figures are median pred icted DBF inhibition as percent of maximum inhibition (Left) 
and time courses by [CONTACT_33237] 334 concentration (Right) . Estimated mean maximum inhibition in DBF 
response from phase 1 study is approximately 93%.  
2.4 Clinical Hypotheses 
The clinical hypothesis is that long-term exposure of AMG 334 will be safe and well 
tolerated in subjects with chronic migraine.   In the CHU substudy, it is hypothesized that 
users will be able to administer a full dose of AMG  334 comparably using either the PFS 
or prefilled AI/pen.  No formal hypotheses will be tested.  
3. EXPERIMENTAL PLAN  
3.1 Study Design 
This is a multicenter, open-label study designed to assess the long-term safety and 
efficacy of AMG 334.  Subjects who  complete the 12-week double-blind treatment phase 
of the AMG 334 20120295 parent study and meet all AMG 334 20130255 eligibility 
criteria will be enrolled into the study.  Enrollment should occur within 14 days after the 
parent study‚Äôs week [ADDRESS_32555]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32556] not yet enrolled in the study will receive open-label  AMG 334 
140 mg every month ( QM) SC for [ADDRESS_32557] already completed the week 28 visit will continue to receive 70 mg QM.   
All subjects will receive open-label AMG 334 QM SC  for 13  months  followed by  a 
12-week safety follow up visit ([ADDRESS_32558] 
[IP]).  
Investigational product (ie, AMG 334 70 mg or 140 mg) will be dosed QM , SC.  
The overall study design is described by a study schema at the end of the protocol 
synopsis section.  
The study endpoints are defined in Section 10.1.1. 
3.2 Number of Sites 
It is anticipated that approximately  60 sites across North America and Europe will 
participate in the study.  The same sites that participate in the parent study will be 
utilized for the s tudy.  All sites in the US, Sweden , and [LOCATION_013] may participate in the 
CHU substudy.  
3.3 Number of Subjects 
Participants in this clinical investigation shall be referred to as ‚Äúsubjects‚Äù.   Up to 
[ADDRESS_32559] is up to 
16 months , which includes the 13-month open-label treatment phase and 3 month 
(12 weeks) s afety follow -up after treatment phase. 
3.5.2 End of Study  
Primary Completion and End of Trial :  The time when the last subject is assessed for 
evaluation in the study  (ie, when the last subject completes the study, which includes the 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32560], or is  discontinued from 
the study). 
4. SUBJECT ELIGIBILITY  
Investigators will be expected to maintain a screening log of all potential study 
candidates that includes limited information about the potential candidate (eg, date of 
screening) .     
Before any  study -specific activities/procedure, the appropriate written informed consent 
must be obtained (see Section 11.1 ).   
4.[ADDRESS_32561] has provided informed consent prior to in itiation of any study -specific 
activities/procedures  
[ADDRESS_32562] safety or interfere with 
the study evaluation, procedures or completion 
Note:  Any ECG abnormality noted by [CONTACT_33238]. 
[ADDRESS_32563] who experienced an SAE in the parent study (AMG 334 20120295) 
for whom the investigator determined that there was a reasonable possibility that 
the event may have been caused by [CONTACT_33239] 
[ADDRESS_32564] demonstrated poorly controlled 
hypertension following randomization into the parent study  
204 Systolic blood pressure (BP) 160 mm Hg and/or diastolic BP 100 mm Hg or 
greater at screening/Day 1 
If the systolic BP  is > 160  mm Hg or diastolic BP is > [ADDRESS_32565] who used excluded concomitant medications between week 8 and week  12 of the parent study  
207 Pregnant (as confirmed by [CONTACT_941] w eek [ADDRESS_32566] of parent study)  or 
breastfeeding, or is a female expecting to conceive during the study, includi ng 
through [ADDRESS_32567]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32568].  Acceptable methods of 
effective birth control include not having intercourse (true abstinence, when this is in line with the preferred and usual lifestyle of the subject), hormonal birth control methods (pi[INVESTIGATOR_3353], shots/injections, impl ants or patches), intrauterine devices, 
surgical contraceptive methods (vasectomy with medical assessment of the surgical success of this procedure or bilateral tubal ligation), or two barrier 
methods (each partner must use one barrier method) with spermici de - males 
must use a condom with spermicide; females must choose either a Diaphragm with spermicide, OR Cervical cap with spermicide, OR Contraceptive sponge with spermicide   
Female subjects not of childbearing potential are defined as any female who: 
‚Ä¢ Is post-menopausal by [CONTACT_969], defined as   
o Age ‚â• 55 years with cessation of menses for 12 or more 
months , OR 
o Age < [ADDRESS_32569] 
2 years , OR  
o Age < [ADDRESS_32570] 
1 year, but currently amenorrheic (eg, spontaneous or 
secondary  to hysterectomy), AND with postmenopausal 
gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels > 40 IU/L) or postmenopausal estradiol levels (< 5 ng/dL) or according to the definition of "postmenopausal range" for the laboratory 
involved.  
OR  
‚Ä¢ Underwent bilateral oophorectomy  OR 
‚Ä¢ Underwent hysterectomy OR  
‚Ä¢ Underwent bilateral salpi[INVESTIGATOR_1656]  
209 Likely to not be able or available to complete all protocol required study visits or 
procedures, and/or to comply with all required study procedures (eg, independent 
completion of electronic diary [eDiary] items) to the best of the subject‚Äôs and investigator‚Äôs knowledge
 
5. SUBJECT ENROLLMENT  
Before subjects begin participation in any study -specific activities/procedures, [COMPANY_010] 
requires a copy of the site‚Äôs written Institutional Review Board /Independent Ethics 
Committee (IRB/IEC ) approval of the protocol, informed consent form  (ICF), and all other 
subject information and/or recruitment material, if applicable (see Sec tion 11.2).  All 
subjects must personally sign and date the IRB/IEC and [COMPANY_010]-approved ICF before 
commencement of study -specific procedures.   
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32571] is enrolled or screen failed (does not meet all screening eligibility criteria , 
refer to Section 4).  The screening phase must not begin prior to the completion of all 
week [ADDRESS_32572]‚Äôs medical record and on the 
enrollment CRF. 
Investigators may re-test laboratory values within the allowed screening window (within 
14 days after the we ek 12 visit of the parent study).  Reasons for a re-test may include: 
‚Ä¢ Laboratory value(s) out of range for unclear reasons  
‚Ä¢ The subject has a medical condition that can be resolved prior to the re-test 
attempt. 
Subject numbers for this study will be an 11 digit number; the first [ADDRESS_32573] be registered as a screen fail in the IVR/IWR System. 
6. TREATMENT PROCEDURES  
6.[ADDRESS_32574] used is 
AMG 334 either in a PFS or prefilled AI/pen. 
6.[ADDRESS_32575]  
The double- blind treatment assignments from the parent study will remain blinded after 
subjects are enrolled into the OLE study until the primary analysis of the 20120295 study  
is conducted.  

 3URGXFW$0*
3URWRFRO1XPEHU'DWH0DUFK 3DJHRI
&21),'(17,$/   $PJHQ,QYHVWLJDWLRQDO3URGXFW$0*
$PJHQLQYHVWLJDWLRQDOSURGXF WZLOOEHPDQXIDFWXUHGDQGSDFNDJHG E\$PJHQ,QFDQG
GLVWULEXWHGXVLQJ$PJHQFOLQLFDOVWXG\GUXJGLVWULEXWLRQSURFHG XUHV$PJHQ
LQYHVWLJDWLRQDOSURGXFWLVDO VRUHIHUUHGWRDV¬≥VWXG\GUXJ¬¥
)RUVXEMHFWVLQ6WXG\$0*ZLOOEHVXSSOLHGLQP /FOHDUJODVVYLDOV
FRQWDLQLQJP/RIPJP/$0*IRUPXODWHGZLWK P0VRGLXPD FHWDWH
ZYVXFURVH ZYSRO\VRUEDWH DWS+ 
6XEMHFWVUDQGRPL]HGDVSDUWRIWKH&+8VXEVWXG\ZLOOEHVXSSOLH GZLWKDVWHULOHVLQJOH
XVHSUHVHUYDWLYHIUHHVROXWLRQIRU6&LQMHFWLRQLQHLWKHUWZR 3)6RUWZR SUHILOOHG$,SHQV
HDFKFRQWDLQLQJP/$0*DWD FRQFHQWUDWLRQRIPJP/IRU PXODWHGZLWK P0
VRGLXPDFHWDWH ZYVXFURVH ZYSRO\VRUEDWH S+ 
'HWDLOHGLQIRUPDWLRQUHJDUGLQJWKHVWRUDJHDQGSUHSDUDWLRQRIL QYHVWLJDWLRQDOSURGXFWZLOO
EHSURYLGHGVHSDUDWHO\LQWKH,QYHVWLJDWLRQDO3URGXFW,QVWUXFWL RQ0DQXDO,3,0
 'RVDJH$GPLQLVWUDWLRQDQG6FKHGXOH
$PJHQLQYHVWLJDWLRQDOSURGXFWLH$0*RUPJZLOOE HGRVHG406&
7KHTXDQWLW\VWDUWGDWHVWDUWWLPHVLQMHFWLRQVLWHVWRSGDW HDQGER[QXPEHURI
LQYHVWLJDWLRQDOSURGXFWDUHWREHUHFRUGHGRQHDFKVXEMHFW¬∂VFD VHUHSRUWIRUP&5)
ZKHQWKHVLWHDGPLQLVWHUVWKH,3,IDVXEMHFWLVHQUROOHGLQ WKH&+8VXEVWXG\WKHER[
QXPEHUSURYLGHGWRWKHVXEMHFWDQGLQIRUPDWLRQREWDLQHGDWWHOH SKRQHYLVLWVVKRXOGEH
UHFRUGHGE\WKHVLWHRQHDFKVXEMHFW¬∂V&5)DVGHVFULEHGLQ 6HFWLRQ 
2YHUGRVHZLWKWKLVSURGXFWKDVQRWEHHQUHSRUWHG
,QYHVWLJDWLRQDOSURGXFWZLOO EHDGPLQLVWHUHGE\DXWKRUL]HGLQYH VWLJDWLRQDOVLWHVWXG\VWDII
DVWKHODVWSURFHGXUHDIWHUDOO RWKHUVWXG\YLVLWSURFHGXUHVKD YHEHHQFRPSOHWHG7KH
RQHIRUPJGRVHRUWZRLQMHFWLRQVIRUPJGRVHZLOOE HDGPLQLVWHUHGLQWRWKH
DQWHULRUDEGRPLQDOZDOOXSSHUWKLJKRUXSSHUDUP7KHLQMHFW LRQVLWHORFDWLRQVKRXOGEH
WKHVDPHLIWZRV\ULQJHVDUHXVHG'XULQJWKH&+8VXEVWXG\WK HVLWHZLOOSURYLGH,3WR
WKHVXEMHFWWRVHOIDGPLQLVWHUWZ RLQMHFWLRQVXVLQJHLWKHU3)6 RU$,SHQVRQWKH
IROORZLQJGD\7KHLQMHFWLRQVLWHORFDWLRQVKRXOGEHWKHVDPH IRUERWKLQMHFWLRQV)RU
IXUWKHUGHWDLOVUHJDUGLQJVHOIDGPLQLVWUDWLRQSURFHGXUHVWKH, QVWUXFWLRQVIRU8VH,)8
VKRXOGEHFRQVXOWHG
6XEMHFWVVKRXOGEHREVHUYHGIRU DSSUR[LPDWHO\PLQXWHVDIWHU ,3DGPLQLVWUDWLRQRQ
GD\CC
ICC
ICCI CC
I
C
CICC
ICCI CCIC
CI
C
CI
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 30 of 84 
CONFIDEN TIAL    Please refer to specific instructions provided in the IPIM for additional information.   
[IP_ADDRESS] Rules for Withholding or Restarting Investigational Product  
Investigational product doses are fixed and will not be adjusted for individual subjects 
during the study.   
At any time during the study, the investigator may discontinue investigational product 
administration for any subject who experiences a severe or life-threatening adverse 
event reported by [CONTACT_33240].  Refer to Section [ADDRESS_32576] are 
to be registered in the IVR/IWR System.  
6.3 Hepatotoxicity Stoppi[INVESTIGATOR_21866] ( ie, alkaline phosphatase [ALP], 
aspartate aminotransferase [AST], alanine aminotransaminase [ALT], total bilirubin 
[TBL]) and/or international normalized ratio [INR] and/or signs/symptoms of hepatitis (as 
described below) may meet the criteria for withholding or permanent discontinuation of 
[COMPANY_010] investigational product or other protocol -required therapi[INVESTIGATOR_33187]-Induced Liver Injury:  Premark eting Clinical Evaluation 
(US FDA, 2009). 
6.3.[ADDRESS_32577] should 
be followed according to the recommendations in Appendix  A (Addit ional Safety 
Assessment Information) for possible drug-induced liver injury (DILI), if ALL of the 
criteria below are met:  
‚Ä¢ TBL > 2x upper limit of normal (ULN) or INR > 1.5 
‚Ä¢ AND increased AST or ALT from the relevant baseline value as specified below:  
Base line AST or ALT value  AST or ALT elevation  
< ULN > 3x ULN  
‚Ä¢ AND no other cause for the combination of the above laboratory abnormalities is 
immediately apparent; important alternative causes for elevated AST/ALT and/or  
TBL values include, but are not limited to: 
‚Ä¢ Hepatobiliary tract disease 
‚Ä¢ Viral hepatitis (eg, Hepatitis A/B/C/D/E, Epstein-Barr Virus, cytomegalovirus, 
Herpes Simplex Virus, Varicella, toxoplasmosis, and Parvo virus ) 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 31 of 84 
CONFIDEN TIAL    ‚Ä¢ Right sided heart failure, hypotension or any cause of hypoxia to the liver causing 
ischemi a.   
‚Ä¢ Exposure to hepatotoxic agents/drugs or  hepatotoxins , including herbal and 
dietary supplements, plants and mushrooms   
‚Ä¢ Heritable disorders causing impaired glucuronidation (eg,  Crigler -Najjar 
syndrome) and drugs that inhibit bilirubin glucuronidation (eg, indinavir, 
atazanavir)  
‚Ä¢ Alpha-one antitrypsin deficiency  
‚Ä¢ Alcoholic hepatitis  
‚Ä¢ Autoimmune hepatitis  
‚Ä¢ Wilson‚Äôs disease and hemochromatosis  
‚Ä¢ Nonalcoholic Fatty Liver Disease including Ste atohepatitis (NASH)  
‚Ä¢ Non-hepatic causes (eg, rhabdomylosis, hemolysis ) 
If an alternative cause for hepatotoxicity is identified or less stringent conditions 
developed than what are noted above, determine (based on patient population and/or 
severity of the hepatotoxicity or event) if [COMPANY_010] investigational produc t should be 
withheld or permanently discontinued, as deemed appropriate for the safety of the 
subject.  
6.3.[ADDRESS_32578] and 
other protocol -required therapi[INVESTIGATOR_014]:  
‚Ä¢ Elevation of either AST or ALT according to the following schedule:  
Baseline AST or ALT value  AST or ALT  elevation  
Any > 8x ULN at any time 
Any > 5x UL N but <  8x ULN for ‚â• 2 weeks  
Any > 5x ULN but <  8x ULN and unable to adhere to enhanced 
monitoring s chedule  
Any > 3x ULN with clinical signs or symptoms that are 
consistent with hepatitis (such as right upper quadrant pain/tenderness, fever, nausea, vomiting, jaundice).   
‚Ä¢ OR: TBL > 3x ULN at any time  
‚Ä¢ OR: ALP > 8x ULN at any time  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32579](s) is withheld, the subject is to  be followed 
according to recommendations in Appendix  A for possible DILI.  Rechallenge may be 
considered if an alternative cause for impaired liver tests (ALT, AST, ALP) and/or 
elevated TBL, is discovered and the laboratory abnormalities resolve to normal or baseline ( Section 6.3.3).   
6.3.[ADDRESS_32580] will be 
permanently discontinued.  Subjects who clearly meet the criteria for permanent discontinuation (as described in Section 6.3.1) should never be rechallenged. 
6.[ADDRESS_32581]‚Äôs CRF  or eDiary . 
During the parent study, the subject and investigator are to agree on the medications for 
the acute treatment of migraine pain and the appropriate dose(s) that the subject may 
take on an as -needed basis throughout the parent and open-label extension study.  
Medications for acute treatment of migraine pain include: simple analgesics, combination 
analgesics, triptans, ergot derivatives, opi[INVESTIGATOR_858].  To avoid confounding the study results, 
new acute medications for treatment of headache pain should not be introduced and 
addition of daily medications that fall into the categories of simple analgesics, combination analgesics, triptans, and ergot-derivatives should be avoided, even if the medication is used for indications other than headache. 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32582] 
dose of IP : 
‚Ä¢ Divalproex sodium, sodium valproate, topi[INVESTIGATOR_052], carbamazepi[INVESTIGATOR_33188], 
‚Ä¢ All beta blockers  (for example: metoprolol, propranolol, timolol, atenolol, 
nadolol, nebivolol, pi[INVESTIGATOR_8405], bis oprolol) , 
‚Ä¢ All tricyclic antidepressants (for example: amitriptyline, nortriptyline, 
protriptyline), 
‚Ä¢ Flunarizine or verapamil , 
‚Ä¢ Venlafaxine, desvenlafaxine, duloxetine or milnacipran,  
‚Ä¢ Botulinum toxin (injected in the head and/or neck region), 
‚Ä¢ Lisinopril ,  
‚Ä¢ Ca ndesartan, 
‚Ä¢ Butterbur, feverfew, magnesium ( ‚â• 600 mg/day), riboflavin (‚â• 100 mg/day) , 
‚Ä¢ Clonidine or guanfacine, 
‚Ä¢ Cyproheptadine, 
‚Ä¢ Methysergide, 
‚Ä¢ Pi[INVESTIGATOR_33189]  
2. The following m edications  are excluded only if used daily throughout the month for 
migraine prophylaxis  between screening and [ADDRESS_32583] dose of IP : 
‚Ä¢ Fluoxetine, fluvoxamine, 
‚Ä¢ Acetazolamide, 
‚Ä¢ Pi[INVESTIGATOR_33190], 
‚Ä¢ Cyclandelate, 
‚Ä¢ Ergot-derivatives , steroids, triptans,  
‚Ä¢ Nicardipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], nimodipi[INVESTIGATOR_33191], but not for migraine pr ophylaxis, the doses  
should remain stable between screening and [ADDRESS_32584] dose of IP .   
3. Investigational drugs, devices or procedures (eg, acupuncture, occipi[INVESTIGATOR_33192], 
transcranial magnetic stimulation)  between screening and [ADDRESS_32585] dose 
of IP . 
6.6 Medical Devices 
The AMG 334 70 mg/mL SureClick Ô£™ AI/pen is a single-use, disposable, handheld 
mechanical injection device that administers a fixed dose of AMG  334 70 mg/mL into 
subcutaneous tissue.  The AMG 334 prefilled AI/pen uses the same components as the 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 34 of 84 
CONFIDEN TIAL    commercially available Enbrel SureClickÔ£® autoinjector but assembled with a HyFlow 
syringe. 
The AMG 334 PFS is a single-use, disposable, manual injection device that administers 
a single dose of AMG 334 into subcutaneous tissue.  [COMPANY_010] has developed the 
AMG 334 PFS presentation using the commercially available sterile 1-mL long glass 
syringe components procured from Becton Dickinson Pharmaceutical Systems (BD).  
In addition, t uberculin s yringes  will be used in this study.  Authorized study staff will use 
the syringes to pull out investigational product from the vials in the subject‚Äôs assigned kit and administer the investigational product to the subject.   
Subjects participating in the CHU s ubstudy will return the AI/pens or PFS back to the 
clinic for reconciliation and disposal by [CONTACT_17472] a plastic box provided by 
[CONTACT_33241].  Medical devices that are not considered test articles may be used in the conduct of the study as part of standard of care (except for AI/pen or PFS).  
These devices, such as alcohol prep pads, are commercially available and are not usually provided or reimbursed by [CONTACT_11337] (except, for example, if required by [CONTACT_1295]).  The investigator will be responsible for obtaining supplies of these devices.   
Detailed information regarding the medical devices will be provided separately in the IPIM.  
6.[ADDRESS_32586](s) or device(s) after it is released to the clinic by [CONTACT_33242], and partners with whom [COMPANY_010] manufactures the material.  This 
includes any products , devices , or combination products provisioned and/or 
repackaged/modified by [CONTACT_11337].  Product(s) or device(s) includes IP.  Any product 
complaint(s) associated with an investigational product or device supplied by [CONTACT_33243].  
7. STUD Y PR OCEDURES  
7.1 Schedule of Assessments  
Refer to the Schedule of Assessments (Table 1 ) for an outline of the procedures 
required at each study visit.  Each study visit during the open-label treatment phase and 
the safety follow -up phase has a window of ¬± [ADDRESS_32587]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32588] in order to assess clinical significance of this data 
as per exclusion criteria.  
All study procedures for a given study visit are to be completed on the same day . 
Investigators are responsible for ensuring that all study procedures are performed as 
specified in the protocol.   
Study visits should be conducted without additional non-protocol therapi[INVESTIGATOR_33193]. 
Refer to the applicable supplemental (eg, laboratory)  manuals for detailed collection and 
handling proc edures.
 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 36 of 84 
CONFIDENTIAL    Table 1 .  Schedule of Assessments 
General Assessments and Administrative Procedures 
 Screening  Day 1a Wk 
4 / 
M1 Wk 
8 / 
M2 Wk 
12 / 
M3 Wk 
16 / 
M4 Wk 
20 / 
M5 Wk 24 / 
M6 Wk 28 / 
M7 Wk 
32 / 
M8 Wk 36 / 
M9 Wk 
40 / 
M10 Wk 
44 / 
M11 Wk 
48 / 
M12 Wk 52 / 
M13 / 
ET Wk 64/M16 
(16 Wks/4M 
After Last 
Dose of IP)  
Informed Consent X                
Physical 
Examination               X  
Weight               X X 
Vital Signs  Xb  X X X X X X X X X X X X X X 
ECG   X  X   Xc   Xd    X  
Concomitant Medications 
Recording   X X X X X X X X X X X X X X X 
IP Administration   X X X X X X X X X X X X X   
SAE/AE Recording   X X X X X X X X X X X X X X X 
Enrollment  X               
Calls to IVR/IWR System
e   X X X X X X X X X X X X X X X X 
Subject Brings eDiary to Site X X X X X   X    X   X  
Page [ADDRESS_32589]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 37 of 84 
CONFIDENTIAL    Table 1.  Schedule of Assessments 
Laboratory Procedures and Clinical Outcome Assessments 
 Screening  Day 
1a Wk 4 
/ M1 Wk 8 
/ M2  Wk 
12 / 
M3 Wk 
16 / 
M4 Wk 20 
/ M5 Wk 
24 / 
M6 Wk 
28 / 
M7 Wk 
32 / 
M8 Wk 
36 / 
M9 Wk 
40 / 
M10 Wk 
44 / 
M11 Wk 
48 / 
M12 Wk 52 / 
M13 / ET Wk 64/M16  
(16 Wks/4M 
After Last Dose 
of IP)  
UDS Testing as needed throughout study based on investigator‚Äôs clini cal suspi[INVESTIGATOR_33194]-
Urine    X X X X X X X X X X X X X  
Pregnancy Test-
Serum                X 
Chemistry, 
Hematology   X  X   Xc   Xd    X X 
Urinalysis                X 
Biomarker 
Development                 X 
PK Sampling         X       X X 
Anti-AMG  334 
Antibodies         X       X X 
COAs   Dailyf  Dailyf   Dailyf  Dailyf  
Migraine Symptom  
Interference Items   Dailyf  Dailyf   Dailyf  Dailyf  
PROMIS  Weeklyf  Weeklyf   Weeklyf  Weeklyf  
MSQ    X X X X X X X X X X X X X  
MIDAS     X   X   X    X  
Novel PRO Substudy: The Migraine Physical 
Function Impact 
Diary (MPFID)   Dailyf  Dailyf   Dailyf  Dailyf  
C-SSRS    X X X X X X X X X X X X X X 
Page [ADDRESS_32590]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 38 of 84 
CONFIDENTIAL    Table 1.  Schedule of Assessments 
Clinical Home Use Substudy Assessments 
 Screening g Day 1h Day 28 visiti Day 29 Telephone 
visit Day 56 visitj Day 57 Telephone 
visit Day 85 visit k/ ETl 
Informed Consent  X       
Randomization to PFS or AI/pen IP self-
administration arm  X      
PFS or AI /pen Instructionm X X      
Physical Examination  X      
Self-administration IP on-site  X      
Self-administration IP at non-clinic setting    X  X  
Study coordinator IP dispense   X  X   
Study coordinator IP reconcile  X   X  X 
Inquiry re: administration of IP     
X   
X  
Review for ADEs  X X X X X X 
Review for AEs/SAEs    X  X  
Product Complaints Recording (if applicable)  X X X X X X 
Page [ADDRESS_32591]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32592] has completed all 12- week procedures of the parent study and within 14 days of the 12- week visit of the parent study.  
b BP should be measured as part of the screening criteria to determine eligibility (no later than at day [ADDRESS_32593] is enrolled via IVR).  Note:  
BP taken at week 12 of the parent study (AMG 334 20120295) should not be used as screening BP.  
c Only for subjects who increased IP to 140 mg at week 12, 16, or 20  
d Only for subjects who increased IP to 140 mg at week 24 or 28  
e Additional steps during IVR/IWR call to accommodate IP dose increase from 70 mg to 140 mg (between week 4 and week 28).  
f Collection will start at the end of the applicable scheduled visit and finish at the beginning of the applicable scheduled visit.  
g Screening must occur 4 weeks prior to the planned start of the CHU substudy (week 8 or week 36 of the 20130255 study ).  IVR System will be adjusted to 
accommodate CHU screening and randomization information as required.  
h Day 1 of the CHU is equivalent to either week 12 or week 40 of the 20130255 study.  
i Day 28 of the CHU is equivalent to either week 16 or week 44 of the 20130255 study.  
j Day 56 of the CHU is equivalent to either week 20 or week 48 of the 20130255 study.  
k Day 85 of the CHU is equivalent to either week 24 or week 52 of the 20130255 study; subject will receive AMG 334 140mg SC administered by  [CONTACT_33244] 20130255 study . 
l ET:  If a subject  early terminates the CHU substudy, he/she may receive administration of AMG 334 140 mg SC at site as per 20130255 protocol  and will continue 
20130255 scheduled procedures and assessments as per 20130255 protocol.  
m Study coordinator will review PFS or AI /pen training materials (Reference Guide and Instructions for Use) with subject . 
 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 40 of 84 
CONFIDENTIAL    7.2 General Study Procedures  
7.2.1 Study Specific Assessments 
[IP_ADDRESS] Informed Consent 
All subjects or legally authorized representatives must personally sign and date the 
[COMPANY_010]/IRB /IEC approved ICF before any study-specific procedures are performed. 
[IP_ADDRESS] Calls to Interactive Voice Response (IVR) / Interactive W eb 
Response (IWR) System  
Sites are to call the Interactive Voice Response (IVR) / Interactive Web Response (IWR) 
System for the following:  to enroll an eligible subject, to obtain the investigational 
product assignment, to register the end of investigational product, and to register study 
early termination (ET) or completion.  Subject data will be collected in the IVR /IWR  
system . 
[IP_ADDRESS] Physical Ex amination 
A complete physical examination (PE) per standard of care (including neurological exam) will be performed on all subjects.   
[IP_ADDRESS] Weight Measurements 
Weight is to be measured without shoes and is  to be recorded on the Physical 
Measurements CRF . 
[IP_ADDRESS] Vital Signs 
The following measurements are to be performed: Systolic/diastolic blood pressure, 
heart rate, and body temperature.   
Blood pressure will be measured in the following manner: 
‚Ä¢ Subjects should be lying in a supi[INVESTIGATOR_33195] 
5 minutes.  The upper arm should be bare without constrictive clothing and 
supported at heart level (such as with a pi[INVESTIGATOR_33196] 13  centimeters  tall). 
‚Ä¢ Caffeine, exercise, and smoking should be avoided for at least 30 minutes prior 
to measurement. 
‚Ä¢ An appropriately -sized cuff (cuff bladder encircling at least 80 percent of the arm) 
should be used to ensure accuracy.  At least two measurements (separated by [CONTACT_12697] 5 minutes) should be made and the average recorded.  If there is a high 
value, it is acceptable to wait approximately 30 minutes  before the next two  blood 
pressure measurements are taken for the purpose of averaging and recording in 
the CRF. 
‚Ä¢ Neither the subject nor the observer (measurer) should talk during measurement. 
The position  selected for a subject should be the same that is used throughout the study 
and documented on the Vital Signs CRF.    
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 41 of 84 
CONFIDENTIAL    If the screening systolic BP is > 160 mm Hg or diastolic BP is > [ADDRESS_32594] should be the same that is used 
throughout the study and documented on the Vital Signs CRF. 
All measurements are to be recorded on the Vital Signs CRF. [IP_ADDRESS] Urine Drug Screening 
During the study, u rine drug tests may be performed at the investigator‚Äôs discretion 
based on clinical suspi[INVESTIGATOR_2798].  Urine samples will be analyzed by [CONTACT_2237].  
For a subject with a positive urine drug screen during the study (except for certain 
prescribed medications), the investigator should consider discontinuing the subject from 
investigational product.  
[IP_ADDRESS] Pregnancy Testing for Women of Childbearing Potential 
Female subjects of childbearing potential will have urine pregnancy tests t hroughout the 
treatment phase and a serum pregnancy test at the safety follow -up visit.  All urine 
pregnancy testing will be performed by [CONTACT_12082]. 
[IP_ADDRESS] Electrocardiogram (ECG)  
The s ubject must be in a supi[INVESTIGATOR_33197] a rested and calm state for at least [ADDRESS_32595] include the following measurements: Heart Rate, QRS, QT, QTc, and PR intervals.  
Sites will use ECG equipment supplied by [CONTACT_11337].  It is the responsibility of the 
investigator to determine if the ECG tracings are consistent with a subject‚Äôs safe 
participation in the study.   The investigator will review and sign the original ECG tracing 
and retain the signed tracing with the subject‚Äôs source documents.  The central reader 
will review all ECGs.  At the request of [COMPANY_010], a copy of the original ECG will be made 
available to [COMPANY_010].   
Any ECG abnormality noted by [CONTACT_33245].  
Please refer to the central ECG  reader manual for details.  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 42 of 84 
CONFIDENTIAL    [IP_ADDRESS] Pharmacokinetic (PK) Sampling 
Blood samples will be collected and assayed for AMG [ADDRESS_32596] after the PK sample has been collected . 
Please refer to the central laboratory manual for instructions on sample collection, processing, and shippi[INVESTIGATOR_33198].  
[IP_ADDRESS] Clinical Outcomes Assessments (COAs) and Electronic Diaries 
(eDiaries)  
Clinical Outcomes Assessments (COAs) will be collected by [CONTACT_33246] a handheld 
electronic diary (eDiary).  The eDiary will collect the following COAs:  
‚Ä¢ Incidence of headache (ie, migr aine with or without aura or non-migraine 
headache)  
‚Ä¢ Time of onset of headache 
‚Ä¢ Time of resolution of headache  
‚Ä¢ Pain severity per headache 
‚Ä¢ Pain features (eg, one-sided, throbbing, pain severity, worsens  with 
exercise/physical activity )  
‚Ä¢ Symp toms (eg, nausea, vomiting, photophobia, phonophobia) and related 
severity  
‚Ä¢ Presence of aura  
‚Ä¢ Use of acute medication  
Subjects will use an eDiary every day between the Day  [ADDRESS_32597]‚Äôs eDiary will also be used for the completion of the following patient-reported 
outcomes (PROs) measures: Migraine symptom interference items  (daily between the 
Day 1 and month 3 visit, between the month 5 and 6 visit, between the month 9 and 
10 visit, and between the month 12 and 13 visit) , Patient Reported Outcomes 
Measurement Information System (PROMIS) Pain Interference Scale short form  (weekly 
between the Day  1 and month 3 visit, between the month 5 and 6 visit, between the 
month 9 and 10 visit, and between the month 12 and 13 visit ), Migraine-specific Quality 

 3URGXFW$0*
3URWRFRO1XPEHU'DWH0DUFK 3DJHRI
&21),'(17,$/  RI/LIH4XHVWLRQQDLUH064PRQWKO\DQG0LJUDLQH'LVDELOLW\ $VVHVVPHQW
4XHVWLRQQDLUH0,'$6HYHU\PRQWKV
5HIHUWRWKHH'LDU\PDQXDOIRUGHWDLOV
 0LJUDLQH6\PSWRP,QWHUIHUHQFH,WHPV
,QGLYLGXDOLWHPVZLOODVVHVVWKHH[WHQWWRZKLFKPLJUDLQHV\PSW RPVLQWHUIHUHGZLWKWKH
VXEMHFW¬∂VGDLO\DFWLYL WLHVZLWKLQWKHSDVWKRXUV
6XEMHFWVZLOOFRPSOHWHWKHPLJUDL QHV\PSWRPLQWHUIHUHQFHLWHPV XVLQJWKHH'LDU\
 3DWLHQW5HSRUWHG2XWFRPHV0HDVXUHPHQW,QIRUPDWLRQ6\VW HP
3520,63DLQ,QWHUIHUHQFH6FDOH6KRUW)RUP
7KH3DWLHQW5HSRUWHG2XWFRPHV0HDV XUHPHQW,QIRUPDWLRQ6\VWHP3 520,6LVD
V\VWHPRIUHOLDEOHSUHFLV HPHDVXUHVRISDWLHQWUHSRUWHGKHDOWK VWDWXV3520,6
LQVWUXPHQWVPHDVXUHFRQFHSWVV XFKDVSDLQIDWLJXHSK\VLFDOIX QFWLRQGHSUHVVLRQ
DQ[LHW\DQGVRFLDOIXQFWLRQ3520,6WRROVFDQEHDGDSWHGIRU XVHDFURVVDZLGH
YDULHW\RIGLVHDVHVDQGFRQGLWLRQV
7KH3520,63DLQ,QWHUIHUHQFH6FDOHVKRUWIRUPLVDLWHPLQVWU XPHQWPHDVXULQJOHYHO
RISDLQLQWHUIHUHQFHRQHQMR\PHQWRIOLIHDELOLW\WRFRQFHQWUD WHGD\WRGD\DFWLYLWLHV
HQMR\PHQWRIUHFUHDWLRQDODFWLYLWL HVGRLQJDFWLYLWLHVDZD\IUR PKRPHDQGVRFLDOL]LQJ
ZLWKRWKHUV7KHUHFDOOSHULRGLVWKHSDVWGD\V$VLQJOHW RWDOVFRUHRILQWHUIHUHQFHLV
JHQHUDWHG
6XEMHFWVZLOOFRPSOHWHWKH3520,63DLQ,QWHUIHUHQFH6FDOHVKRUW IRUPXVLQJWKHH'LDU\
 0LJUDLQHVSHFLILF4XDOLW\RI/LIH4XHVWLRQQDLUH064
CCI

 3URGXFW$0*
3URWRFRO1XPEHU'DWH0DUFK 3DJHRI
&21),'(17,$/   0LJUDLQH'LVDELOLW\$VVHVVPHQW4XHVWLRQQDLUH0,'$6
6XEMHFWVZLOOFRPSO HWHWKH0,'$6XVLQJWKHH'LDU\
 1RYHO352,QVWUXPHQW6XEVWXG\2SWLRQDO
6XEMHFWVPD\HOHFWWRSDUWLFLSDWHL QDVHSDUDWHQRYHO352VXEVW XG\WRHYDOXDWHWKH
LPSDFWRIPLJUDLQH6XEMHFWVPD\HOHFWWRSDUWLFLSDWHLQERWK WKH1RYHO352,QVWUXPHQW
VXEVWXG\DQGWKH&+8VXEVWXG\7KH03 ),'DVHOIDGPLQLVWHUHG LWHPLQVWUXPHQW
WKDWPHDVXUHVSK\VLFDOIXQFWLRQLQJZLOOEHXVHGWRPHDVXUHSK\ VLFDOLPSDLUPHQWDQGWKH
LPSDFWRIPLJUDLQHRQVXEMHFWV¬∂HYHU \GD\DFWLYLWLHV3DUWLFLSD WLRQLQWKHVXEVWXG\LV
RSWLRQDO6XEMHFWVZKRHOHFWWRSDUWLFLSDWHLQWKLV352VXEVWX G\ZLOOEHUHTXLUHGWR
SURYLGHVHSDUDWHLQIRUPHGFRQVHQWDQGPXVWEHZLOOLQJWRFRPSOH WHWKH03),'GDLO\
GXULQJWKHVWXG\WLPHSRLQWVQRWHGEH ORZ$SSUR[LPDWHO\VXE MHFWVZLOOSDUWLFLSDWHLQ
WKLVVXEVWXG\
7KH0LJUDLQH3K\VLFDO)XQFWLRQ,PSDFW'LDU\03),' CCI
CCI

 3URGXFW$0*
3URWRFRO1XPEHU'DWH0DUFK 3DJHRI
&21),'(17,$/  6XEMHFWVSDUWLFLSDWLQJLQWKHQRYHO352VXEVWXG\ZLOOFRPSOHWH WKH03),'HYHU\GD\
XVLQJWKHH'LDU\EHWZHHQWKH' D\DQGPRQWKYLVLWEHWZHHQW KHPRQWKDQGYLVLW
EHWZHHQWKHPRQWKDQGYLVLWDQGEHWZHHQWKHPRQWKDQG YLVLW6XEMHFWVPD\
EHJLQWRSDUWLFLSDWHLQWKHVXEV WXG\DWDQ\WLPHRQRUEHIRUHW KHPRQWKYLVLW
 &OLQLFDO+RPH8VH6XEVWXG\2SWLRQDO/LPLWHGWR6XEMH FWVLQ86
*HUPDQ\DQG6ZHGHQ
8SWRVXEMHFWVPD\HOHFWWRSDU WLFLSDWHLQDVHSDUDWH&+8VX EVWXG\WRDVVHVV
VXEMHFWV¬∂DELOLW\WRVHOIDGPL QLVWHUPJRI$0*IRULQK RPHXVHXVLQJHLWKHUWZR
3)6RUWZRSUHILOOHG$,SHQV,WLVK\SRWKHVL]HGWKDWXVHUVZL OOEHDEOHWRVHOIDGPLQLVWHU
DIXOOGRVHRI$0*FRPSDUDEO\XVLQJHLWKHUWKH3)6RU$,SH Q1RIRUPDO
K\SRWKHVHVZLOOEHWHVWHG6DIHW\DQGWROHUDELOLW\RI$0* VHOIDGPLQLVWHUHGXVLQJ
WZRP/3)6RUWZRP/$,SHQVZLOODOVREHDVVHVVHG3DUWLF LSDWLRQLQWKHVXEVWXG\
LVRSWLRQDODQGQRDGGLWLRQDOVDPSO HVDUHFROOHFWHGIRUWKHVXE VWXG\6XEMHFWVZKRHOHFW
WRSDUWLFLSDWHLQWKLV&+8VXEVWXG\ZLOOEHUHTXLUHGWRSURYLGH VHSDUDWHLQIRUPHGFRQVHQW
DQGPXVWPHHWWKHIROORZLQJLQFOXVLRQDQGQRQHRIWKHH[FOXVLRQ FULWHULD
,QFOXVLRQ&ULWHULD6XEMHF WVHQWHULQJWKHVXEVWXG\DWZHHN RIWKHVWXG\
PXVWKDYHUHFHLYHGRSHQODEHO PJ$0*VLQFHGD\RIWKH VWXG\
6XEMHFWVHQWHULQJWKHVXEV WXG\DWZHHNPXVWKDYHUHFHLYHGRS HQODEHOPJ
$0*VLQFHZHHNRIWKHVWXG\RUHDUOLHU
([FOXVLRQ&ULWHULD8QUHOL DELOLW\DVDVWXG\SDUWLFLSDQWEDVHG RQWKHLQYHVWLJDWRU¬∂VRU
GHVLJQHH¬∂VNQRZOHGJHRIWKHVXEMHFW>HJXQZLOOLQJQHVVWRDGKH UHWRWKHSURWRFRO
XQZLOOLQJWRVHOILQMHFWXVLQJHLWKHUDQ$,SHQRUD3)6DIWHU UHYLHZRIWKH,)8DQG
5HIHUHQFH*XLGH5*@
6XEMHFWVPXVWSURYLGHL QIRUPHGFRQVHQWDQGUHYLHZWKH SUHILOOHG$,SHQRU3)6,)8DQG
5*HLWKHUDWZHHNRUDWZHHNWRGHWHUPLQHLIWKH\ZLVKWR HQUROOLQWKHVXEVWXG\DW
ZHHNVRUUHVSHFWLYHO\$IWHUFRQILUPLQJWKDWWKHRSWLRQ DO&+8VXEVWXG\,&)KDV
EHHQVLJQHGVXEMHFWVZKRPHHWDOOLQ FOXVLRQH[FOXVLRQFULWHULD PD\EHUDQGRPL]HGYLD
,956\VWHPWRVHOIDGPLQLVWHU$0*XVLQJHLWKHUWKH3)6RU$ ,SHQDSSUR[LPDWHO\
VXEMHFWVLQHDFKDUP3K\VLFDOH[DPLQDWLRQRIWKHVXEMHFW ZLWKDIRFXVRQDQ\VNLQ
DEQRUPDOLWLHVLQDUHDVWKDWPD\EHLQMHFWHGZLOOEHREWDLQHGDW HQUROOPHQWIRUWKLV
VXEVWXG\DGYHUVHGHYLFHHIIHFWV$'(VZLOOEHDVVHVVHGRQ&+8 GD\GD\DQG
GD\DWVLWHDQGRQ&+8GD\VDQGDVVHVVHGE\WHOHSKR QHYLVLW$GYHUVHCCI
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 46 of 84 
CONFIDENTIAL    event, serious adverse event, and concomitant medication assessment, vital signs 
measurement, ECGs , urinalysis, and blood draw for serum chemistry and hematology 
analytes and anti -AMG 334 antibody assay will be performed as described in the 
20130255 study.   Subjects will be randomized to self-administer either 2x70mg AMG 
334 via PFS or 2x70mg AMG 334 via prefilled AI/pen.  On the CHU day 1 visit  (week 12 
or week 40 of AMG 334 20130255 study)  the site should review the IFU and RG for 
AI/pen or PFS with the subject prior to administration of IP  (depending upon device 
subject has been randomized to use).  On day 1 of the substudy, s ubjects will 
self-administer IP, AMG 334 140 m g SC with either two x 70 mg prefilled  AI/pen or two 
x 70 mg PFS, under clinical site supervision.  Subjects will be provided a box containing 
either 2x70 mg PFS or 2x70 mg prefilled AI/pen at the CHU day 28 (week 16 or week 
44 of AMG 334 20130255 study) and day 56 (week 20 or week 48 of AMG 334 
20130255 study) visits and will self -administer IP individually without supervision at 
home on d ays [ADDRESS_32598] administered a full, partial , or no dose of AMG 334 
(after explaining that a full dose means that the entire volume of both PFS or AI /pens 
were  injected) and will document the subject‚Äôs response in the CRF .  If the subject was 
not able to administer a full dose of AMG 334, the site staff will inquire further to 
determine if the subject experienced a device failure or use error that prevented the 
full-dose administration.  Safety will be monitored as adverse events, serious adverse 
events, and ADEs.  Day 85 is the end of the CHU substudy  and sites will inquire about 
ADEs.  Day 85 of the CHU substudy is equivalent to either week 24 or  week 52 of the 
20130255 study; site will administer AMG [ADDRESS_32599] 
early terminates the CHU s ubstudy, he/she may receive administration of AMG [ADDRESS_32600] to early 
terminate the CHU substudy will not be replaced.   
[IP_ADDRESS] Columbia-Suicide Severity Rating Scale (C -SSRS) 
The C -SSRS is a clinical rating of suicide behavior and ideation, which consists of a 
maximum of [ADDRESS_32601] (severity of 4 or 5) and reports of actual, 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32602] of care. 
[IP_ADDRESS] Concomitant Medications Recording 
Data on all concomitant therapi[INVESTIGATOR_33199].  Acute medications  taken during aura or to treat headache will be 
collected in the eDiary  during the periods of daily diary collection, and data will include 
the medication name, date of administration, time of administration, dose, and route of 
administration.  Acute medications ongoing at the time of enrollment w ill be collected in 
the CRF.  Any new or change to dose regimen for an ongoing acute medication will also 
be collected in the CRF. 
Other concomitant therapi[INVESTIGATOR_33200], and data will include the generic drug 
name/treatment, indication, and dates of administration.   
Refer to Sec tion 6.[ADDRESS_32603] of 
treatments excluded during the study. [IP_ADDRESS] Adverse Event Reporting 
Adverse event information should be collected throughout the study and recorded at 
each study visit.  Refer to Section 9  for details.   
[IP_ADDRESS] Laboratory Assessments 
Sites must utilize the central laboratory for subject eligibility and assessments during the 
study , unless stated otherwise.  Laboratory samples will be processed and sent to the 
central laboratory which is responsible for either completing the assessment or shippi[INVESTIGATOR_33201] , depending on the assessment.  The central laboratory 
will be utilized for parameters such  as complete blood count (CBC) with differential, 
serum chemistry, urine drug screening and urinalysis.  Samples for PK testing, 
biomarker development, and anti -AMG [ADDRESS_32604] the samples to [COMPANY_010] (or designee) for 
analys is.  Sites will use their local laboratory for urine pregnancy testing (for WOCBP ).   
Please refer to the central laboratory manual for instructions on the collection, processing, and shippi[INVESTIGATOR_26172]. 
Any sample collected according to the Schedule of Assessments (Table 1 ) may be 
analyzed for any of the tests outlined in the protocol and for any tests necessary to 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32605] safety.  This includes testing to ensure analytical methods produce 
reliable and valid data throughout the course of the study.  This may also include, but is not limited to, investigation of unexpected results, incurred sample reanalysis, and 
analyses for method transfer and comparabil ity. 
Analyte Listing ( all run by [CONTACT_12115], unless otherwise noted as 
‚Äú[COMPANY_010]/designee‚Äù or ‚Äúlocal‚Äù laboratory.  Please refer to the central laboratory manual for 
the complete listing of analytes run by [CONTACT_2237] ):   
Chemistry  Urinalys is Hematology  
Sodium  Other Labs  
Specific gravity  RBC  Pregnancy testing- urine 
(local)  
Potassium  pH Hemoglobin  Pregnancy testing- serum  
Chloride  Blood  Hematocrit  Urine drug screening  
Bicarbonate  Protein  MCV  PK ([COMPANY_010]/designee)  
Total protein  Glucose  MCH  Anti-AMG  334 antibodies 
([COMPANY_010]/designee)  
Albumin  Bilirubin  MCHC  Biomarker development 
([COMPANY_010]/designee)  
Calcium  WBC  RDW  
Magnesium   RBC  Reticulocytes  
Phosphorus   Epi[INVESTIGATOR_33202]  ‚Ä¢ Bands/stabs  
Creatinine  
eGFR MDRD  
Uric acid   Crystals  ‚Ä¢ Eosinophils  
‚Ä¢ Basophils  
Total bilirubin  
CPK   ‚Ä¢ Lymphocytes  
‚Ä¢ Neutrophils   
Direct bilirubin    ‚Ä¢ Monocytes   
Alk phos    Myeloblasts   
AST (SGOT)   ‚Ä¢ Promyelocytes   
ALT (SGPT)   ‚Ä¢ Myelocytes   
Cholesterol    ‚Ä¢ Metamyelocytes   
HDL   ‚Ä¢ Atypi[INVESTIGATOR_33203]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 49 of 84 
CONFIDENTIAL    7.2.2 Screening 
After confirming the ICF has been signed, the following procedures are to be completed: 
‚Ä¢ Vital signs  
‚Ä¢ Subject brings eDiary to site  
‚Ä¢ Screening call to IVR/IWR System  
7.2.3 Day 1  
Review laboratory and central reader ECG report from week 12 visit of AMG  334 
20120295 study  
Vital signs  (if not measured at Screening visit)  
After confirming subject eligibility, the following procedures are to be completed: ‚Ä¢ Enroll ment o f the subject using the IVR/IWR System  
‚Ä¢ Concomitant medications  recording  
‚Ä¢ Serious and non-serious adverse event recording 
‚Ä¢ Subject brings eDiary to site  
‚Ä¢ Novel PRO Substudy:  The MPFID (optional)  
‚Ä¢ Administration of AMG [ADDRESS_32606] procedure performed at each study visit. 
7.2.4 Open-label Treatment  Phase 
The following procedures are to be completed during the open-label treatment phase at 
time points designated in the Schedule of Assessments ( Table 1 ). 
‚Ä¢ Physical examination (including neurological examination) as per standard of care  
‚Ä¢ Weight  
‚Ä¢ Vital s igns 
‚Ä¢ ECG  
‚Ä¢ Laboratory assessments using the central laboratory: urine drug screen (based upon 
the investigator‚Äôs clinical suspi[INVESTIGATOR_2798]) , chemistry and hematology panels  
‚Ä¢ Urine pregnancy test 
‚Ä¢ PK sampling 
‚Ä¢ AMG 334 antibody collection  
‚Ä¢ COAs, migraine symptom interference items and PROMIS  
‚Ä¢ C-SSRS 
‚Ä¢ MSQ and MIDAS.  The subject will complete these PROs while in the clinic, using 
the eDiary.  For each study visit, these PROs should be completed prior to invasive 
procedures (eg, blood draws).    
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 50 of 84 
CONFIDENTIAL    ‚Ä¢ Novel PRO Substudy: The MPFID  (optional)  
‚Ä¢ Concomitant medications recording  
‚Ä¢ Serious and non-serious adverse event recording 
‚Ä¢ Subject brings eDiary to site  
‚Ä¢ Administr ation of AMG [ADDRESS_32607] procedure performed at each study visit. 
‚Ä¢ Increase IP to [ADDRESS_32608] available opportunity at 
either week 4, 8, 12, 16, 20, 24 or 28  (during regular IP Assignment IVR S/IWR S call)  
‚Ä¢ CHU Substudy in US, [LOCATION_013] , and Sweden (optional ) 
‚Ä¢ After confirming the ICF has been signed, the following procedures are to be 
completed:   
‚Ä¢ Screening (20130255 w eek 8 or 36):  Review of IFU and RG for both PFS and 
prefilled AI/pen with subject  
‚Ä¢ After confirming subject eligibility, the following procedures are to be completed: 
‚Ä¢ Day 1 (20130255 w eek 12 or 40):   
‚Ä¢ Randomization of the subject to PFS or prefilled AI/pen self-
administration using the IVR/IWR System  
‚Ä¢ Site to instruct subject on how to self-administer AMG 334 with either 
PFS or prefilled AI/pen by [CONTACT_33247]  
‚Ä¢ Physical e xamination of subject with particular attention to any skin 
abnormalities in areas that might be used for IP self-administration 
‚Ä¢ Subject self- administration using either PFS or prefilled AI/pen under site 
supervision  
‚Ä¢ Review for ADEs , adverse events, and serious adverse events 
‚Ä¢ Study Coordinator to reconcile IP (PFS or prefilled AI/pen) 
‚Ä¢ Product Complaint Recording (if applicable)  
‚Ä¢ Day 28 (20130255 w eek 16 or 44):   
‚Ä¢ Study coordinator dispenses PFS or prefilled AI/pen to subject for 
self-administration on d ay 29  
‚Ä¢ Telephone call time scheduled for d ay 29 (Note, telephone visit must 
occur after subject has self-administered IP)  
‚Ä¢ Product Complaint Recording (if applicable)  
‚Ä¢ Day 29:   
‚Ä¢ Subject self- administers AMG 334 using either PFS or prefilled AI/pen in 
non-clinic setting 
‚Ä¢ Telephone visit with study coordinator  to inquire of subject if he/she 
administered a full, partial , or no dose of AM G 334  
‚Ä¢ If the subject was not able to administer a full dose of AMG 334, the site 
staff will inquire further to determine if the subject experienced a device 
failure or use error that prevented the full -dose administration 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 51 of 84 
CONFIDENTIAL    ‚Ä¢ Review adverse events/ADEs/ serious  adverse events 
‚Ä¢ Product Complaint Recording (if applicable)   
‚Ä¢ Day 56 (20130255 week 20 or 48):   
‚Ä¢ Study coordinator dispenses PFS or prefilled AI/pen to subject for 
self-administration on day 57 
‚Ä¢ Telephone call time scheduled for d ay 57 (Note, telephone visit must 
occur after subject has self-administered IP)  
‚Ä¢ Product Complaint Recording (if applicable)  
‚Ä¢ Day 57:   
‚Ä¢ Subject self- administers AMG 334 using either PFS or prefilled AI/pen in 
non-clinic setting 
‚Ä¢ Telephone visit with study coordinator to inquire of subject if he/she 
administered a full, partial , or no dose of AMG 334 
‚Ä¢ If the subject was not able to administer a full dose of AMG 334, the site 
staff will inquire further to determine if the subject experienced a device 
failure or use error that prevented the full -dose administration 
‚Ä¢ Review adverse events /ADEs/serious adverse events  
‚Ä¢ Product Complaint Recording (if applicable)   
‚Ä¢ Day 85 (20130255 week 24 or 52): End of CHU s ubstudy   
‚Ä¢ Study coordinator  inquires about any ADEs, product complaint recording 
(if applicable)   
‚Ä¢ Subject continues  all 20130255 study assessments  and IP is 
administered at site as per 20130255 protocol  using vial formulation 
7.2.5 Safety Follow -up 
The following procedures are to be completed for the safety follow -up as designated in 
the Schedule of Assessments (Table 1 ): 
‚Ä¢ Register subject‚Äôs end of study using the IVR/IWR System   
‚Ä¢ W eight 
‚Ä¢ Vital s igns 
‚Ä¢ Laboratory assessments using the central laboratory: urine drug screen (based upon 
the investigator‚Äôs clinical suspi[INVESTIGATOR_2798]), urinalysis, pregnancy testing (serum), chemistry 
and hematology panels  
‚Ä¢ PK sampling 
‚Ä¢ Biomarker development collection  
‚Ä¢ AMG 334 antibody serum sampling 
‚Ä¢ C-SSRS  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 52 of 84 
CONFIDENTIAL    ‚Ä¢ Concomitant medications recording  
‚Ä¢ Serious and non-serious adverse event recording.  (Note: Serious and n on-serious 
adverse events  are to be collected through [ADDRESS_32609]).   
7.3 Antibody Testing Procedures 
Blood sample(s) for antibody testing are to be collected at timepoints outlined in the 
Schedule of Assessments for the measurement of anti -AMG 334  binding antibodies.  
Samples testing positive for binding antibodies will also be tested for neutralizing 
antibodies and may be further characterized for quantity/titer, isotype, affinity and presence of imm une complexes.  Additional blood samples may be obtained to rule out 
anti-AMG [ADDRESS_32610] at the 
final scheduled study visit will be asked to return for additional follow -up testing.  This 
testing is to occur approximately every 3 months starting from when the site has been 
notified of the positive result, until:  (1)  neutralizing antibodies are no longer detectable 
or (2) the subject has been followed for  a period of at least 1 year (¬±  4 weeks)  post 
administration of investigational product.  All follow -up results, both positive and negative 
will be communicated to the sites.  More frequent testing (eg, every month) or testing for 
a longer period of time may be requested in the event of safety -related concerns.  
Follow -up testing is not required where it is established that the subject did not receive 
AMG 334. 
Subjects who test positive for binding, non-neutralizing antibodies and have clinical 
sequelae that are considered potentially related to an anti -AMG 334  antibody response 
may also be asked to return for additional follow -up testing.   
7.4 Biomarker Development  
Blood samples are to be collected for biomarker development, and samples collected for 
other testing could be utilized for biomarker development.  Biomarkers are objectively 
measured and evaluated indicators of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.  Biomarker development can 
be useful in identify ing disease subtypes, guiding  therapy, and/or predicting  disease 
severity.   
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32611](s) designed to identify subjects most likely to 
respond positively or negatively to AMG 334.    
7.5 Sample Storage and Destruction  
Any sample collected according to the Schedule of Assessments (Table 1 ) can be 
analyzed for any of the tests outlined in  the protocol and for any tests necessary to 
minimize risks to study subjects.  This includes tes ting to ensure analytical methods 
produce reliable and valid data throughout the course of the study.  This can also 
include, but is not limited to, investigation of unexpected results, incurred sample reanalysis, and analyses for method transfer and comparability.  
All samples and associated results will be coded prior to being shipped from the site for analysis or storage.  Samples will be tracked using a unique identifier that is assigned to the samples for the study.  Results are stored in a secure database to ensure confidentiality.   
If informed consent is provided by [CONTACT_423], [COMPANY_010] can do additional testing on 
remaining samples (ie, residual and back -up) to investigate and better understand 
migraine, the dose response and/or prediction of response to AMG 334, characterize 
antibody response, and characterize aspects of the molecule (eg, mechanism of 
action/target, metabolites).  Results from this analysis are to be documented and 
maintained, but are not necessarily reported as part of this study.  Samples can be 
retained for up to [ADDRESS_32612]‚Äôs medical record and are not to be 
made available to the subject, members of the family, the personal physician, or other third parties , except as specified in the informed consent.  
The subject retains the right to request that the sample material be destroyed by [CONTACT_21947] .  Following the request from the subject, the investigator is to 
provide the sponsor with the required study and subject number so that any remaining samples and any other components from the cells can be located and destroyed.  
Samples will be destroyed once all protocol -defined procedures are completed.  
However, information collected from samples prior to the request for destruction, will be 
retained by [CONTACT_11337].  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 54 of 84 
CONFIDENTIAL    The sponsor is the exclusive owner of any data, discoveries, or derivative materials from 
the sample materials and is responsible for the destruction of the sample(s) at the 
request of the subject through the i nvestigator , at the end of the storage period, or as 
appropriate (eg, the scientific rationale for experimentation with a certain sample type no longer justifies keepi[INVESTIGATOR_21878]).  If a commercial product is developed from this research project, the sponsor owns the commercial product.  The subject has no 
commercial rights to such product and has no commercial rights to the data, information, 
discoveries, or derivative materials gained or produced from the sample.   
Refer to Section 11.[ADDRESS_32613] s‚Äô Decision to Withdraw  
Subjects have the right to withdraw from the study at any time and for any reason 
without prejudice to their  future medical care by [CONTACT_8018].  
Subjects  can decline to continue receiving investigational product and/or other 
protocol -required therapi[INVESTIGATOR_33204].  If this occurs, the investigator is to discuss with the subject the 
appropriate processes for discontinuation from investigational product or other 
protocol -required therapi[INVESTIGATOR_33205]  (Table 1 ) and collection of data, including 
endpoints and adverse events.  The i nvestigator  must document the change to the 
Schedule of Assessments (Table 1 ) and the level of follow-up that is agreed to by [CONTACT_1560] ( eg, in person, by [CONTACT_756]/mail, through family/friends, in 
correspondence/communication with other physicians, from review of the medical records ).   
Withdrawal of consent for a study means that the subject does not wish to receive further protocol -required therapi[INVESTIGATOR_21882] , and the subject does not wish to or is 
unable to continue further study participation.  Su bject data up to withdrawal of consent 
will be included in the analysis of the study , and where permitted, publicly available data 
can be included after withdrawal of consent.  The investigator is to discuss with the 
subject appropriate procedures for withdrawal from the study.   
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 55 of 84 
CONFIDENTIAL    8.2 Investigator or Sponsor Decision to Withdraw  or Terminate 
Subjects‚Äô Participation Prior to Study Completion 
The i nvestigator and/or sponsor can decide to withdraw a subject(s) from investigational 
product and/or other protocol -required therapi[INVESTIGATOR_014], protocol procedures , or the study as a 
whole at any time prior to study completion.    
Subjects may be eligible for continued treatment with [COMPANY_010] investigational product(s) 
and/or other protocol -required therapi[INVESTIGATOR_21883] a separate protocol or as provided for by [CONTACT_21956]‚Äôs regulatory mechanism, based on parameters consistent with 
Section 12.1. 
8.[ADDRESS_32614](s) or procedural 
assessments include  any of the following:  
‚Ä¢ Subject request   
‚Ä¢ Safety concern (eg, due to an adverse event, failure to follow contraception, breast 
feeding, requirement for treatment not allowed in the protocol, and/or protocol 
requirements)  
‚Ä¢ Death 
‚Ä¢ Lost to follow -up 
‚Ä¢ Decision by s ponsor  (other than subject request, safety concern, lost to follow -up) 
‚Ä¢ Lack of efficacy  
8.3.[ADDRESS_32615] from the study  are: 
‚Ä¢ Decision by [CONTACT_3211]  
‚Ä¢ W ithdrawal of consent from study  
‚Ä¢ Death 
‚Ä¢ Lost to follow -up 
9. SAFETY DATA COLLECTION, RECORDING, AND REPORTING  
9.[ADDRESS_32616]‚Äôs medical record.   
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 56 of 84 
CONFIDENTIAL    The definition of adverse events includes  worsening of a pre-existing medical condition.  
Worsening indicates that the pre-existing medical condition or underlying disease  
(eg, diabetes, migraine headaches, gout) has increased in severity, frequency, and/or 
duration more than would be expected, and/or has an association with a significantly 
worse outcome than expected.  A pre -existing condition that has not worsened more 
than anticipated (ie, more than usual fluctuation of disease)  during the study or 
involves an intervention such as elective cosmetic surgery or a medical procedure while 
on study , is not considered an adverse event.   
An adverse device effect (ADE) is any adverse event related to the use of a 
medical device.  Adverse device effects include adverse events resulting from insufficient or inadequate instructions for use, adverse events resulting from any malfunction of the device, or adverse events resulting from use error or from 
intentional misuse of the device. 
The investigator‚Äôs clinical judgment is used to determine whether a subject is to be 
removed from treatment due to an adverse event.  In the event a subject, or subject‚Äôs 
legally acceptable representati ve requests to withdraw from protocol -required therapi[INVESTIGATOR_33206], refer to Section 8.[ADDRESS_32617] 1 of the 
following serious criteria:  
‚Ä¢ Fatal 
‚Ä¢ Life threatening (places the subject at immediate risk of death)  
‚Ä¢ Requires in -patient hospi[INVESTIGATOR_1081] 
‚Ä¢ Results in persistent or significant disability/incapacity  
‚Ä¢ Congenital anomaly/birth defect  
‚Ä¢ Other medically important serious event  
An adverse event would meet the criterion of ‚Äúrequires hospi[INVESTIGATOR_059]‚Äù, if the event necessitated an admission to a health care facility (eg, overnight stay).   
If an i nvestigator considers an event to be clinically important, but it does not meet any 
of the serious criteria, the event could be classified as a serious adverse event under the 
criterion of ‚Äúother medically important serious event‚Äù.  Examples of such events could 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 57 of 84 
CONFIDENTIAL    include allergic bronchospasm, convulsions, blood dyscrasias, DILI (see Appendix  A for 
drug-induced liver injury reporting criteria), or events that necessitate an emergency 
room visit, outpatient surgery, or urgent intervention. 
9.[ADDRESS_32618] through the end of study  are reported using the applicable CRF (eg, Adverse 
Event Summary), including events that are reported to the Event Adjudication 
Committee for adjudication. 
The investigator must assign the following adverse event attributes:  
‚Ä¢ Adverse event diagnosis or syndrome(s), if known (if not known, signs or symptoms), 
‚Ä¢ Dates of onset and resolution (if resolved) , 
‚Ä¢ Severity,  
‚Ä¢ Assessment of relatedness to investigational product and/or any study -mandated 
activity or procedure, and 
‚Ä¢ Action taken. 
The adverse event grading scale used will be the Common Terminology Criteria for 
Adverse Events (CTCAE).  The grading scale used in this study is described in 
Appendix  A.  The criteria for grade 4 in the CTCAE grading scale differs from the 
regulatory criteria for serious adverse events.  It is left to the investigator‚Äôs judgment to 
report these grade [ADDRESS_32619].  This relationship is indicated by a ‚Äúyes‚Äù or ‚Äúno‚Äù response to the 
question:  ‚ÄúIs there a reasonable possibility that the event may have been caused by [CONTACT_33248]?‚Äù   
During the CHU, the i nvestigator must assess whether the adverse event is possibly 
related to the IP and/or device.  This relationship is indicated by a ‚Äúyes‚Äù or ‚Äúno‚Äù response 
to the question:  Is there a reasonable possibility that the event may have been caused 
by [CONTACT_33249].  The investigator must assess whether the adverse event is possibly related to 
the PFS or prefilled AI/pen used to administer IP.  The relationship is indicated by a 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 58 of 84 
CONFIDENTIAL    ‚Äúyes‚Äù or ‚Äúno‚Äù response to the question:  Is there a reasonable possibility that the event 
may have been caused by [CONTACT_8121]? 
The investigator must assess whether the adverse event is possibly related to any 
study -mandated activity  or procedure (eg, administration of investigational product, 
device(s)  [including any screening procedure(s)]).  This relationship is indicated by a 
‚Äúyes‚Äù or ‚Äúno‚Äù response to the question:  ‚ÄúIs there a reasonable possibility that the event 
may have been caused by a study activity /procedure (eg, administration of 
investigational product, device[s]) ?‚Äù  
The investigator is responsible for reviewing laboratory test results and determining 
whether an abnormal value in an individual study subject represents a clinically significant change from the subject‚Äôs baseline values.  In general, abnormal laboratory findings without clinical significance (based on the investigator's judgment) are not to be 
recorded as adverse events.  For example, hematuria caused by [CONTACT_33250].  However , laboratory value changes that 
require treatment or adjustment in current therapy are considered adverse events.  Where applicable, clinical sequelae (not the laboratory abnormality) are to be recorded 
as the adverse event. 
The i nvestigator is expected to follow reported adverse events until stabilization or 
reversibility. 9.2.[ADDRESS_32620]‚Äôs medical record and are submitted to [COMPANY_010].   All 
serious adverse events must be submitted to [COMPANY_010] within 24 hours following the 
investigator‚Äôs knowledge of the event via the applicable CRF, including events that are 
reported to the Event Adjudication Committee for adjudication.  
After the protocol -required reporting period defined above, the investigator does not 
need to actively monitor subjects for serious adverse events.  However, if the 
investigator becomes aware of a serious adverse event after this protocol -required 
reporting period, the investigator will report the event to [COMPANY_010] within 24 hours following the investigator‚Äôs knowledge of the event.  Serious adverse events  reported outside of 
the protocol -required reporting period will be captured within the safety database as 
clinical trial cases for the purposes of expedited reporting.  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32621] assess whether the serious adverse event is possibly related to 
any study -mandated activity or procedure.  This relationship is indicated by a ‚Äúyes‚Äù or 
‚Äúno‚Äù response to the question:  ‚ÄúIs there a reasonable possibility that the event may have 
been caused by a study activity/procedure?‚Äù  
The investigator is expected to follow reported serious adverse events until stabilization 
or reversibility.  
New information relating to a previously reported serious adverse event must be 
submitted to [COMPANY_010].   All new information for serious adverse events must be sent to 
[COMPANY_010] within [ADDRESS_32622] be consistent with that recorded on the applicable CRF (eg, Adverse Event Summary CRF).  
If a subject is permanently withdrawn from protocol -required therapi[INVESTIGATOR_21889] a 
serious adverse event, this information must be submitted to [COMPANY_010].  
[COMPANY_010] will report serious adverse events and/or suspected unexpected serious adverse 
reactions as required to regulatory authorities, investigators /institutions, and IRBs/IECs 
in compliance with all reporting requirements accor ding to local regulations and good 
clinical practice.  
The investigator is to notify the appropriate IRB/I EC of serious adverse events occurring 
at the site and other adverse event reports received from [COMPANY_010], in accordance with 
local procedures and statutes.  
9.[ADDRESS_32623]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 60 of 84 
CONFIDENTIAL    events will be based on clinical, laboratory, and/or imaging data ordered at the treating 
physician‚Äôs discretion to assess and treat the event. 
The Event Adjudication Committee will be comprised of a group of experienced 
clinicians with expertise in cardiology and neurology.  The Event Adjudication Committee 
will be responsible for the review and adjudication of the selected adverse events in a blinded manner.  The responsibilities and procedures of the Event Adjudication Committee will be described in the Event Adjudication Committee Charter. 
9.[ADDRESS_32624], report the pregnancy to [COMPANY_010] as specified below . 
The pregnancy should be reported to [COMPANY_010]‚Äôs Global Patient Safety within 24 hours of 
the investigator‚Äôs knowledge of the event of a pregnancy.  Report a pregnancy on the 
Pregnancy Notification Worksheet ( Appendix  C).  [COMPANY_010]‚Äôs Global Patient Safety will 
follow -up with the investigator regarding additional information that may be 
requested.  
If a female subject becomes pregnant during the study, the investigator should 
attempt to obtain information regarding the birth outcome and health of the infant.  
If a male subject's female partner becomes pregnant, the investigator should 
discuss obtaining information regarding the birth outcome and health of the infant 
from the pregnant  partner. 
If the outcome of the pregnancy meets a criterion for immediate classification as a 
serious a dverse event (eg, female subject experiences a spontaneous abortion, 
stillbirth, neonatal deat h, or there is a fetal or neonatal congenital anomaly) , the 
investigat or will report the event as a serious adverse event. 
If a lactation case occurs while the female subject is taking investigational product 
through [ADDRESS_32625], report the lactation case 
to [COMPANY_010] as specified below.  
Any lactation case should be reported to [COMPANY_010]‚Äôs Global Patient Safety within 24 hours  
of the investigator‚Äôs knowledge of event.  Report a lactation case on the Lactation 
Notification Worksheet (Appendix  C).  [COMPANY_010] Global Patient Safety will follow -up 
with the investigator regarding additional information that may be requested. 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 61 of 84 
CONFIDENTIAL    10. STATISTICAL CONSIDERATIONS   
10.1 Study Endpoints, Analysis Sets, and Covariates 
10.1.1 Study Endpoints 
[IP_ADDRESS] Primary Endpoint  
The primary endpoint for the study is subject incidence of adverse events . 
‚Ä¢ Subject-reported outcome of attempted full -dose administration at each of d ay 29 
and day 57  CHU Substudy  
[IP_ADDRESS] Secondary Endpoints 
‚Ä¢ Change from baseline in monthly migraine days at assessment timepoints  
‚Ä¢ Achievement of at least a 50% reduction from baseline in monthly migraine days at 
assessment timepoints  
‚Ä¢ Change from baseline in  monthly acute migraine-specific medication treatment days 
at assessment timepoints  
‚Ä¢ Change from baseline in cumulative monthly headache hours at assessment 
timepoints  
‚Ä¢ Subject incidence of adverse events, serious adverse events, and adverse device effects  CHU Substudy  
[IP_ADDRESS] Exploratory Endpoints 
‚Ä¢ Change from baseline in monthly migraine attacks  at assessment timepoints   
‚Ä¢ Change from baseline in monthly headache (migraine and non-migraine headache) days at assessment timepoints  
‚Ä¢ Change from baseline in monthly moderate and severe headache (migraine and non-migraine headache) days  at assessment timepoints  
‚Ä¢ Reduction from baseline in monthly average severity of migraine pain at assessment 
timepoints  
‚Ä¢ Change from baseline in monthly average severity of migraine related symptoms 
(nausea, vomiting, phonophobia, photophobia) for qualified migraine headaches at 
assessment timepoints  
‚Ä¢ Change from baseline in migraine-specific quality of life, as measured by [CONTACT_33251], 
version 2.1 at assessment timepoints  
‚Ä¢ Change from baseline in migraine-related disability, as measured by [CONTACT_33252] 
‚Ä¢ Change from baseline in pain interference with daily activities and migraine-specific 
impact, as measured by [CONTACT_33253]  
‚Ä¢ Change in physical impairment over time as measured by [CONTACT_33254]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 62 of 84 
CONFIDENTIAL    ‚Ä¢ Change in impact on everyday activities over time as measured by [CONTACT_33231]  
‚Ä¢ AMG 334 exposure 
[IP_ADDRESS] Clinical Outcome Assessments - Definition of Terms Included in 
Endpoints 
Clinical outcome assessments will be determined via diary data. 
‚Ä¢ Migraine Day: Any calendar day in which the subject experiences a qualified 
migraine headache (onset, continuation, or recurrence of the migraine headache).  A 
qualified migraine headache is defined either as a migraine without aura or a 
migraine with aura as outlined below:  
1. A migraine without aura, lasting for ‚â• 4 continuous hours, and meeting criteria a 
and/or  b: 
a) ‚â• 2 of the following pain features:   
‚Ä¢ Unilateral  
‚Ä¢ Throbbing 
‚Ä¢ Moderate to severe 
‚Ä¢ Exacerbated with exercise/physical activity  
b) ‚â• 1 of the associated symptoms:   
‚Ä¢ Nausea and/or vomiting  
‚Ä¢ Photophobia and phonophobia  
OR 
2. A migraine with aura and meeting criteria a and b: 
a) Meeting ‚â• 1 of the following fully reversible aura symptoms:  
‚Ä¢ Visual  
‚Ä¢ Sensory  
‚Ä¢ Speech and/or language  
‚Ä¢ Retinal  
‚Ä¢ Brainstem  
b) Aura is accompanied, or followed within 60 minutes, by [CONTACT_33223] 
‚â• [ADDRESS_32626] took a triptan or ergot-derivative on a calendar day, then it will be 
counted as a migraine day regardless of the duration and pain features/associated 
symptoms.  
‚Ä¢ Headache Day:  Any calendar day in which the subject experiences a qualified 
migraine or non-migraine headache (initial onset, continuation or recurrence of the 
headache lasting ‚â• 4 continuous hours , or a headache of any duration for which 
acute medication was administered (Refer to Section 6.4) for treatment of headache 
pain. 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 63 of 84 
CONFIDENTIAL    ‚Ä¢ Headache Day with moderate or severe intensity: Any calendar day in which the 
subject experiences a headache, with headache pain lasting ‚â• [ADDRESS_32627] takes a triptan or ergot-derivative for headache pain 
‚Ä¢ Monthly Migraine Days:  Number of migraine days in any 28-consecutive day interval 
relative to study day 1.  See above for the definition of a migraine day. 
‚Ä¢ Monthly Headache Days:  Number of headache days in any 28-consecutive day 
interval relative to study day 1.  See above for the definition of a headache day.   
‚Ä¢ Migraine Attack:  An epi[INVESTIGATOR_33207] a triptan or ergot-derivative to treat headache or aura.  The 
following rules will be used for distinguishing an attack  of long duration from two 
attack s, or for distinguishing between attack s and relapses:  
a) A migraine attack  which is interrupted by [CONTACT_33222], and then 
recurs within 48 hours after onset of the attack  will be considered as one attack, 
and not two. 
b) An attack  primarily treated successfully with medication but with relapse within 
48 hours  will be considered as one attack . 
10.1.2 Analysis Sets 
The full analysis set (FAS) includes all subjects who were enrolled in the study  and 
received at least one dose of investigational product.   All subjects participating in the 
PRO substudy and have at least one monthly score for the MPFID will be included in the 
PRO analysis set.  All subjects enrolled in the CHU substudy will be included in the CHU 
analysis set.    
10.1.3 Covariates and Subgroups 
Since no formal statistical testing is planned for either safety or efficacy endpoint, no  
covariate analysis will be performed.  
Subgroups: 
‚Ä¢ Region (North America vs. o ther) 
‚Ä¢ Medication overuse (Yes vs. n o) 
10.2 Sample Size Considerations 
All subjects who completed the 12-week double-blind treatment phase of the parent 
study, meet the inclusion and exclusion criteria for the 20130255 OLE study, and 
consent to receive IP  will be eligible to be enrolled.  Up to 651 subjects may participate 
in the study.     
In the CHU Substudy:  Assuming 5% of subjects per treatment group discontinue IP and 
90% of the remaining subjects respond that they administered a full dose, then the anticipated distribution of responses per treatment group at a planned visit would be 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 64 of 84 
CONFIDENTIAL    5% categorized as not attempting due to discontinuing IP, 85.5% responding that they 
administered a full dose, and 9.5% responding that they did not administer a full dose.  
The associated 95% confidence interval halfwidths with 40 subjects per group are 
6.8%, 10.9%, and 9.1%, respectively.  The anticipated 95% confidence interval halfwidth 
for the difference between treatment groups in the proportion of subjects administering a 
full dose is 15.4%.  The discontinuation rate is expected to be less than 5% and the rate 
of administering a full dose is expected to be greater than 90%, and therefore these 
calculations are anticipated to be lower bounds.  Calculations were performed using 
nQuery Advisor 7.0.  
10.3 Planned Analyses  
10.3.1 Interim Analyses  
On an annual basis or until an administrative decision is made to close the study, 
descriptive statistics of safety and efficacy will be produced for use in the annual report and/or to support publications, if warranted. 
An analysis of the data collected as part of the CHU substudy will be performed once the 
substudy has been completed.  In addition, an additional interim analysis may  be 
performed as deemed necessary.  However, there are no stoppi[INVESTIGATOR_33208]. 
10.3.[ADDRESS_32628] one dose of AMG 334 in the study will be 
included in the data analys is according to their allocated treatment groups in the parent 
study, as well as an overall analysis (of all subjects in the OLE study). 
For the purpose of primary analysis for secondary and exploratory endpoints in the 
20130255 OLE study, baseline is defined as baseline of the AMG 334 20120295 parent 
study (from the first day subject used eDiary in baseline at week -4 study visit through the day prior to study day 1).  However, change from the parent study Month [ADDRESS_32629]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32630] disposition of all enrolled subjects , 
the demographic data, baseline disease characteristics, efficacy, and safety endpoints. 
10.4.2 Efficacy Endpoint 
Descriptive summaries on efficacy endpoints will be provided by [CONTACT_33255] 334 20120295 parent study  (ie, AMG 334 70 mg, AMG 334 140 mg), treatment 
group of the AMG 334 20130255 study (AMG [ADDRESS_32631] is 140 mg), and study visit using 
the efficacy analysis set.  
10.4.[ADDRESS_32632] (ie, safety  analysis set) will be analyzed based on the maximum 
actual treatment dose received using safety analysis set. 
The Medical Dictionary for Regulatory Activities (MedDRA) version [ADDRESS_32633]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 66 of 84 
CONFIDENTIAL    Shift tables based on CTCAE grade relative to baseline will be tabulated by [CONTACT_33256] . 
The analyses of vital signs (systolic blood pressure, diastolic blood pressure, heart rate, 
temperature, weight) will include summary statistics of change from baseline measure 
over time by [CONTACT_1570]. 
The ECG measurements from this clinical study will be performed as per standard of 
care for routine safety monitoring, rather than for purposes of assessment of potential 
QTc effect.  Since these evaluations may not necessarily be performed under the 
rigorous conditions expected to lead to meaningful evaluation of QTc data, summaries 
and statistical analyses of ECG measurements are not planned, and these data would not be expected to be useful for meta-analysis with data from other studies. 
The incidence and percentage of subjects who develop anti -AMG 334 antibodies 
(binding and if positive, neutralizing) at any time will be tabulated by [CONTACT_1570]. The analysis of s ubject- reported outcome of attempted full -dose administration at each 
of day [ADDRESS_32634] report of full dose administration will be considered a ‚Äúyes‚Äù response, and a 
subject report of partial or no dose administered will be considered a ‚Äúno‚Äù response.  The 
proportion of each possible pattern of responses across the two visits will also be estimated.  Ninety -five percent confidence intervals will be provided for each group and 
the difference in proportions between the groups. 
10.4.4 Others  
Descriptive summaries  of the primary and secondary endpoints may be provided by 
[CONTACT_33257] 10.1.3. 
11. REGULATORY OBLIGATIONS  
11.1 Informed Consent 
An initial sample informed consent form is provided for the investigator to prepare the 
informed consent document to be used at his or her site.  Updates to the template are to be communicated formally in writing from the [COMPANY_010] Clinical  Study Manager to the 
investigator .  The written informed consent document is to be prepared in the 
language(s) of the potential patient population.  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32635]‚Äôs participation in the clinical study, the investigator is responsible for 
obtaining written informed consent from the subject after adequate explanation of the 
aims, methods, anticipated benefits, and potential hazards of the study and before any 
protocol -specific screening procedures or any investigational products are administered.     
The investigator is also responsible for asking the subject if the subject has a primary 
care physician and if the subject agrees to have his/her primary care physician informed 
of the subject‚Äôs participation in the clinical study.  If the subject agrees to such 
notification, the investigator is to inform the subject‚Äôs primary care physician of the 
subjec t‚Äôs participation in the clinical study.  If the subject does not have a primary care 
physician and the i nvestigator will be acting in that capacity, the investigator is to 
document such in the subject‚Äôs medical record.   The acquisition of informed consent a nd 
the subject‚Äôs agreement or refusal of his/her notification of the primary care physician is  
to be documented in the subject‚Äôs medical records, and the informed consent form is to 
be signed and personally dated by [CONTACT_33258].  The original signed informed consent form is to be 
retained in accordance with institutional policy, and a copy of the signed consent form is 
to be provided to the subject.  
11.[ADDRESS_32636]/Independent  Ethi cs Committee 
A copy of the protocol, proposed informed consent form, other written subject 
information, and any proposed advertising material must be submitted to the IRB/IEC  for 
written approval.  A copy of the written approval of the protocol and informed consent form must be received by [CONTACT_33259].  
The investigator must submit and, where necessary, obtain approval from the IRB/IEC  
for all subsequent protocol amendments  and changes to the informed consent 
document.  The investigator is to notify the IRB/IEC of deviations from the protocol or 
serious adverse events occurring at the site and other adverse event reports received from [COMPANY_010], in accordance with local procedur es. 
The investigator is responsible for obtaining annual IRB/IEC  approval/renewal 
throughout the duration of the study.  Copi[INVESTIGATOR_1093] i nvestigator‚Äôs reports and the 
IRB/IEC  continuance of approval must be sent to [COMPANY_010].  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32637]‚Äôs confidentiality is maintained for 
documents submitted to [COMPANY_010].   
‚Ä¢ Subjects are  to be identified by a unique subject identification number .   
‚Ä¢ Where permitted, date of birth is to be documented and formatted in accordance with 
local laws and regulations.   
‚Ä¢ On the CRF demographics page, in addition to the unique subject identification 
number, include the age at time of enrollment.   
‚Ä¢ For Serious Adverse Events reported to [COMPANY_010], subjects are to be identified by [CONTACT_21969] , initials  (for faxed reports, in accordance with 
local laws and regulations), and date of birth (in accordance with local laws and 
regulations ). 
‚Ä¢ Documents that are not submitted to [COMPANY_010] (eg, signed informed consent forms) are 
to be kept in confidence by [CONTACT_093] , except as described below. 
In compliance with Federal regulations/ International Conference on Harmonisation 
Tripartite Guideline on Good Clinical Practice (ICH GCP ) Guidelines , it is required that 
the investigator and institution permit authorized representatives of the company, of the 
regulatory agency(s), and the IRB/IEC direct access to review the subject‚Äôs original 
medical records for verification of study-related procedures and data.  Direct access includes examining, analyzing, verifying, and reproducing any records and reports that 
are important to the evaluation of the study.  The investigator is obligated to inform and 
obtain the consent of the subject to permit such individual s to have access to his/her 
study -related records, including personal information. 
11.4 Investigator Signatory Obligations 
Each clinical study report is to be signed by [CONTACT_1720], in the case of 
multi -center studies, the coordinating investigator . 
The c oordinating investigator, identified by [CONTACT_11337], will be any or all of the following:  
‚Ä¢ a recognized expert in the therapeutic area 
‚Ä¢ an investigator who provided significant contributions to either the design or 
interpretation of the study  
‚Ä¢ an investigator contributing a high number of eligible subjects  
12. ADMINISTRATIVE AND LEGAL OBLIGATIONS  
12.1 Protocol Amendments and Study Termination 
[COMPANY_010] may  amend the protocol  at any time.  After [COMPANY_010] amends the protocol, 
Investigator is to return the signed Investigator‚Äôs Signature [CONTACT_33266].  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 69 of 84 
CONFIDENTIAL    The IRB/IEC  must be informed of all amendments and give approval.  The investigator 
must  send a copy of the approval letter from the IRB/IEC to [COMPANY_010].  
[COMPANY_010] reserves the right to terminate the study at any time.  Both [COMPANY_010] and the 
investigator  reserve the right to terminate the i nvestigator ‚Äôs participation in the study 
according to the Clinical Trial Agreement.  The investigator is to notify the IRB/IEC  in 
writing of the study‚Äôs completion or ET and send a copy of the notification to [COMPANY_010].   
Subjects may be eligible for continued treatment with [COMPANY_010] investigational product by [CONTACT_21970]‚Äôs regulatory mechanism.  
However, [COMPANY_010] reserves the unilateral right, at its sole discretion, to determine whether to supply [COMPANY_010] investigational product , and by [CONTACT_21971], after 
termination of the study and before the product is available commercially. 
12.[ADDRESS_32638] of appropriately qualified persons to whom he/she 
has delegated study duties.  All persons authorized to make entries and/or corrections 
on CRFs will be included on the [COMPANY_010] Delegation of Authority Form.  
Source documents are original documents, data, and records from which the subject‚Äôs 
CRF data are obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, 
and correspondenc e. 
CRF entries may be considered source data if the CRF is the site of the original 
recording (ie, there is no other written or electronic record of data).  In this study, the 
MSQ and MIDAS CRF s can be used as source documents.  
The i nvestigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation, suitable for 
inspection at any time by [CONTACT_21972]/or applicable regulatory authorities.   
Elements to include:  
‚Ä¢ Subject files containing completed CRFs , informed consent forms, and subject 
identification list  
‚Ä¢ Study files containing the protocol with all amendments , Investigator‚Äôs Brochure, 
copi[INVESTIGATOR_21892], and all correspondence to and from the IRB/IEC  
and [COMPANY_010]  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 70 of 84 
CONFIDENTIAL    ‚Ä¢ Investigational product- related correspondence including proof of receipts, 
Investigational Product Accountability Record(s), Return of Investigational Product 
for Destruction Form(s), Final Investigational Product Reconciliation State ment, as 
applicable. 
‚Ä¢ Medical devices  (ie, syringes)  documentation, as applicable. 
In addition, all original source documents supporting entries in the CRFs must be 
maintained and be readily available. 
Retention of study documents will be governed by [CONTACT_21973]. 
12.3 Study Monitoring and Data Collection 
The [COMPANY_010] representative(s) and regulatory authority inspectors are responsible for 
contact[CONTACT_21974], 
upon request, inspecting the various records of the clinical study (eg, CRFs and other 
pertinent data) provided that subject confidentiality is respected. 
The [COMPANY_010] clinical m onitor is responsible for verifying the CRFs at regular intervals 
throughout the study to verify adherence to the protocol; completeness, accuracy, and 
consistency of the data; and adherence to local regulations on the conduct of clinical research.  The c linical mo nitor is to have access to subject medical records and other 
study -related records needed to verify the entries on the CRFs. 
The investigator agrees to cooperate with the clinical monitor to ensure that any 
problems detected in the course of these monitoring visits, including delays in completing CRFs, are resolved. 
In accordance with ICH GCP and the sponsor‚Äôs audit plans, this study may be selected 
for audit by [CONTACT_21975]‚Äôs Global Compliance Auditing function (or 
designees).  Inspection of site facilities (eg, pharmacy, protocol -required therapy storage 
areas, laboratories) and review of study -related records will occur to evaluate the study 
conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements. 
All paper CRFs  are to be typed or filled out with a black ballpoint pen and must be 
legible.  
‚Ä¢ Corrections to paper forms are to be made by a single line stroke through the error 
and insertion of the correction above or beside the error.  The change must be 
initialed and dated by [CONTACT_1720] a member of the study staff authorized by 
[CONTACT_33260].  No erasures, correction 
fluid, or tape are to be used.   
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 71 of 84 
CONFIDENTIAL    ‚Ä¢ Corrections to electronic forms are automatically documented through the software‚Äôs 
‚Äúaudit trail‚Äù.  
‚Ä¢ To ensure the quality of clinical data across all subjects and sites, a clinical data 
management review is performed on subject data received at [COMPANY_010].  During this 
review, subject data are checked for consistency, omissions, and any apparent 
discrepancies.  In addition, the data are reviewed for adherence to the protocol and 
GCP.  To resolve any questions arising from the clinical data management review 
process, data queries and/or site notifications are sent to the site for completion and 
returned to [COMPANY_010].  
‚Ä¢ The investigator signs (or inscribe s and seal s, if applicable) and dates the indicated 
places on the CRF.  These signatures indicate that the investigator inspected or 
reviewed the data on the CRF the data queries, and the site notifications, and agrees 
with the content. 
Data capture for this study is planned to be electronic:  
‚Ä¢ All source documentation supporting entries into the CRFs must be maintained and 
readily available. 
‚Ä¢ Updates to CRFs will be automatically documented through the software‚Äôs ‚Äúaudit trail‚Äù. 
‚Ä¢ To ensure the quality of clinical data across all  subjects and sites, a clinical data 
management review is performed on subject data received at [COMPANY_010].  During this 
review, subject data are checked for consistency, omissions, and any apparent 
discrepancies.  In addition, the data are reviewed for adherence to the protocol and 
GCP.  To resolve any questions arising from the clinical data management review 
process, data queries and/or site notifications are created in the EDC system 
database for site resolution and closed by [CONTACT_33261].  
‚Ä¢ The i nvestigator signs only the Investigator Verification Form for this electronic data 
capture study.  This signature [CONTACT_21990], the data queries, and the site notifications, and agrees with the 
content.  
[COMPANY_010] (or designee) will perform Self-Evident Corrections  (SEC) to obvious data errors 
in the clinical trial database.  SECs will be documented in the eCRF instructions 
available in the EDC system .  Examples of obvious data errors that may be corrected 
by [CONTACT_11337] (or designee) include deletion of obvious duplicate data (eg, same results 
sent twice with the same date with different visit- week 4 and ET ) and clarifying ‚Äúother, 
specify‚Äù if data are provided (eg, race, physical examination).  Each investigative site will  
be provided a list of the types of corrections applied to study data at the initiation of the trial and at study closeout.   
12.4 Investigator Responsibilities for Data Collection 
The i nvestigator is responsible for comply ing with the requirements for all assessments 
and data collection (including subjects not receiving protocol -required therapi[INVESTIGATOR_014]) as 
stipulated in the protocol for each subject in the study.  For subjects who withdraw prior 
to completion of all protocol -required visits and are unabl e or unwilli ng to continue the 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 72 of 84 
CONFIDENTIAL    Schedule of Assessments (Table 1 ), the investigator can search publicly available 
records [where permitted]) to ascertain survival status.  This ensures that the data sets 
produced as an outcome of the study is/are as comprehensive as possible.   
12.[ADDRESS_32639] be completed in English.  TRADENAMESÔ£® (if used) for concomitant 
medications may be entered in the local language.  Consult the country -specific 
language requirements. 
All written information and other material to be used by [CONTACT_33262].   
12.6 Publication Policy  
Authorship of any publications resulting from this study will be determined on the basis 
of the Inter national Committee of Medical Journal Editors (ICMJE ) 
Recommendations for the Conduct of Reporting, Editing, and Publications of 
Scholarly Work in Medical Journals, which states:  
‚Ä¢ Authorship credit should be based on (1) substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of data; (2) drafting the 
article or revising it critically for important intellectual content; (3) final approval of the version to be published; (4) Agreement to be accountable for all aspects of the work 
in ensuring that questions related to the accuracy or integrity of any part of the work 
are appropriately investigated and resolved.  Authors  should meet conditions 1, 2, 3, 
and 4. 
‚Ä¢ When a large, multi center group has conducted the work, the group should identify 
the individuals who accept direct responsibility for the manuscript.  These individuals 
should fully meet the criteria for authorship defined above. 
‚Ä¢ Acquisition of funding, collection of data, or general supervision of the researc h 
group, alone, does not justify authorship. 
‚Ä¢ All persons designated as authors should qualify for authorship, and all those who 
qualify should be listed.  
‚Ä¢ Each author should have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. 
All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) 
based on this study must be submitted to [COMPANY_010] for review.  The Clinical Trial 
Agreement among the institution, investigator, and [COMPANY_010] will detail the procedures for, 
and timing of, [COMPANY_010]‚Äôs review of publications.  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32640]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 74 of 84 
CONFIDENTIAL    13. REFERENCES 
Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained 
from over 1,500 patients receiving topi[INVESTIGATOR_33209]. 
Pain Med. 2008;9:175-185. 
AMG 334 Investigator‚Äôs Brochure.  Thousand Oaks, CA.  [COMPANY_010] Inc.  
Ashina BL, Bendtsen L, Jensen R, Schifter S, Olesen J.  Evidence for increased plasma 
levels of calcitonin gene -related peptide in migraine outside of attacks. Pain. 
2000;86:133 -138. 
Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic 
migraine: Results from the double-blind, randomized, placebo-controlled phase of the 
PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803. 
Brandes JL, Saper JR, Diamond M, et al. Topi[INVESTIGATOR_33210]: a 
randomized controlled trial. JAMA.  2004;291:965 -973. 
Connor KM, Shapi[INVESTIGATOR_33211], Diener HC, et al. Randomized, controlled trial of telcagepant 
for the acute treatment of migraine. Neurology. 2009;73(12):970-977. 
Diener H, Bussone G, Van Oene J, Lahaye M, Schwalen S, Goadsby P J.  
TOPMAT -MIG-201(TOP -CHROME) Study Group.  Topi[INVESTIGATOR_33212]: a randomized, double-blind, placebo-controlled study.  Cephalalgia.  
2007;27:814 -823. 
Diener H C, Dodick D W, Goadsby P J, Lipton R B, Olesen J, Silberstein S D.  Chronic 
migraine-classification, characteristics and treatment.  Nat Rev Neurol .  2012;8:162-1 71. 
Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic 
migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-814. 
Durham PL. CGRP receptor antagonists: a new choice for acute treatment of migraine? 
Curr Opin Investig Drugs. 2004;5:731 -735. 
Eikermann-H aerter K, Can A, Ayata C. Pharmacological targeting of spreading 
depression in migraine. Expert Rev Neurother . 2012 ;12(3): 297-306. 
Eikermann-Haerter K , Ayata C. Cortical spreading depression and migraine. Curr Neurol 
Neurosci Rep. 2010;10(3):167-1 73.  
Evers S,  Afra E,  Frese A, et al . EFNS Guideline on the drug treatment of migraine ‚Äì 
revised report of an EFNS task force.  Eur J Neurology . 2009;16: 968‚Äì 981. 
Goadsby [CONTACT_33263], Lipton RB, Ferrari MD. Migraine ‚Äì current understanding and treatment. N 
Engl J Med. 2002;364(4):257-270. 
Goadsby [CONTACT_33263], Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral 
circulation of humans during migraine headache. Ann Neurol . 1990;28:183-187. 
Grimwood S , Hartig PR.  Target site occupancy: emerging generalizations from cl inical 
and preclinical studies.  Pharmacol Ther .  2009;122:281-301. 
Ho AP, Dahl √∂f CG, Silberstein S D, et al. Randomized, controlled trial of telcagepant over 
four migraine attacks. Cephalalgia. 2010;30(12):1443-1457.  
Ho TW, Ferrari MD, Dodick DW, et al.  Efficacy and tolerability of MK -0974 
(telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, 
parallel -treatment trial.  Lancet. 2008;372:2115-2123. 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 75 of 84 
CONFIDENTIAL    Hostetler ED, Joshi AD, Sanabria-Boh√≥ rquez S, et al. In vivo quantification of calcitonin 
gene-related peptide receptor occupancy by [CONTACT_33264] [11C]MK -4232. J Pharmacol Exp 
Ther.  2013;347:478-486. 
Houston DS, Vanhoutte PM. Serotonin and the vascular system. Role in health and 
disease and implications for therapy. Drugs. 1986;31:149-163. 
Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann NY Acad Sci. 1990;600:587-598; discussion 598-200. 
International Committee of Medical Journal Editors, Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals:  Writing and Editing for Biomedical 
Publication. 2013. 
http://www.icmje.org/ . Assessed September 2013. 
Katsarava Z, Buse D C, Manack A N, Lipton R B.  Defining the differences between 
epi[INVESTIGATOR_33213].  Curr Pain Headache Rep.  2012;16:86-92. 
Kraenzlin ME, Ch'ng JL, Mulderry PK, Ghatei MA, Bloom SR .  Infusion of a novel 
peptide, calcitonin gene -related peptide (CGRP) in man.  Pharmacokinetics and effects 
on gastric acid secretion and on gastrointestinal hormones.  Regul Pept.  
1985;10:189 -197. 
Lassen LH, Haderslev PA, Jacobsen  VB, Iversen HK, Sperling B, Olesen J.  CGRP may 
play a causative role in migraine.  Cephalalgia.  2002;22:54-61. 
Lenz R, Silberstein S, Dodick D, Reuter U, Ashina M, et al. Results of a randomized, 
double-blind, placebo controlled, phase 2 study to evaluate the efficacy and safety of 
AMG 334 for the prevention of epi[INVESTIGATOR_17730]. Cephalalgia. 2015; 35(6S):5. Abstract 
OR02.  
Lipton RB, Chu M K.  Conceptualizing the relationship between chronic migraine and 
epi[INVESTIGATOR_17730].  Expert Rev Neurother. 2009;9:1451-1454. 
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. AMPP Advisory  
Group: Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343 -349. 
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the [LOCATION_002]: d ata from the American Migraine Study II. Headache. 
2001;41:[ADDRESS_32641] BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 
2004;350:1104-1110. 
Poyner DR. Calcitonin gene-related peptide: multiple actions, multiple receptors. 
Pharmacol. Ther. 1992;56:23-51.  
Rudolf K, Eberlein W, Engel W, et al.  Development of human calcitonin gene-related 
peptide (CGRP) receptor antagonists. 1.  Potent and selective small molecule CGRP 
antagonists.   1-[N2 -[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H) -oxoquinazolin-3-yl) -1-
pi[INVESTIGATOR_33214]]carbonyl]-D-tyrosyl] -l-lysyl] -4-(4-pyridinyl)pi[INVESTIGATOR_3746]: the first CGRP 
antagonist for clinical trials in acute migraine.  J Med Chem .  2005;48:5921-5931. 
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E.  Evidence-based 
guideline update: pharmacologic treatment for epi[INVESTIGATOR_33215].  Neurology . 2012;78:1337-1345. 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 76 of 84 
CONFIDENTIAL    Silberstein SD , Lipton R B, Dodick D W, et al.  Efficacy and safety of topi[INVESTIGATOR_33216]: a randomized, double-blind, placebo-controlled trial.  
Headache.  2007;47:[ADDRESS_32642], telcagepant (MK-0974). Br J Clin Pharmacol. 2010;69:15-22. 
Stovner LJ , Andree C.  Prevalence of headache in Europe: a review for the Eurolight 
project.  J He adache Pain. 2010;11:289‚Äì 299. 
Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation 
of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193-210. 
Sun H, et al. Headache. 2015;55(suppl 3):132. Abstract OR12. 
Wang X, Yue TL, Barone FC, et al. Discovery of adrenomedullin in rat ischemic cortex 
and evidence for its role in exacerbating focal brain ischemic damage. Proc Natl Acad 
Sci [LOCATION_003]. 1995;92:[ZIP_CODE] -[ZIP_CODE]. 
[LOCATION_002] Food Drug Administration.  Guidance for Industry Drug -Induced 
Liver Injury:  Premarketing Clinical Evaluation.  
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf .  Accessed 
05 April  2016.  
Zi
mmermann U, Fischer JA, Frei K, Fischer AH, Reinscheid RK, Muff R. Identification of 
adrenomedullin receptors in cultured rat astrocytes and in neuroblastoma x glioma hybrid cells (NG108-15). Brain Res. 1996;724:238-245. 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32643]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 78 of 84 
CONFIDENTIAL    Appendix A .  Additional Safety Assessment Information 
The Common Terminology Criteria for Adverse Events Version 4 (CTCAE  v4) is 
available at the following location:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  Adverse Event Grading Scale  
Grade  Clinical Description  
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated  
2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL*  
3 Severe or medically significant but not immediately life- threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self care ADL**  
4 Life-threatening consequences; urgent intervention indicated  
5 Death related to AE  
A semi-colon indicates ‚Äòor‚Äô within the description of the grade.  
Activities of Daily Living (ADL):  
* Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, 
managing money, etc.  
** Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, 
and not bedridden.  
Drug -induced Liver Injury Reporting and Additional Assessments  
To facilitate appropriate monitoring for signals of DILI, cases of concurrent AST or ALT 
and TBL and/or  INR elevation according to the criteria specified in Section Reporting  
6.3 require 
the following: 
‚Ä¢ The event is to be reported to [COMPANY_010] as a serious adverse event within 24 hours  of 
discovery or notification of the event (ie, before additional etiologic investigations 
have been concluded)  
‚Ä¢ The appropriate CRF (eg, Adverse Event CRF) that captures information necessary 
to facilitate the evaluation of treatment-emergent liver abnormalities is to be 
completed and sent to the [COMPANY_010].  
Other events of hepatotoxicity and potential DILI are to be reported as serious adverse 
events if they meet the criteria for a serious adverse event defined in Section 9.2.2. 
All subjects in whom investigational product(s) or protocol -required therapi[INVESTIGATOR_33217]/are 
withheld (either permanently or conditionally) due to potential DILI as specified in Additional Clinical Assessments and Observation  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32644] or ALT elevations >[ADDRESS_32645] are to 
undergo a period of ‚Äúclose observation‚Äù until abnormalities return to normal or to the 
subject‚Äôs baseline levels.  Assessments that are to  be performed during this period 
include:  
‚Ä¢ Repeat AST, ALT, ALP, bilirubin (total and direct), and INR within 24 hours  
‚Ä¢ In cases of TBL > 2x ULN or INR  > 1.5, retesting of liver tests, BIL (total and direct 
bilirubin ), and INR is to be performed every [ADDRESS_32646](s) or protocol -required therapi[INVESTIGATOR_33218]/have been 
discontinued AND the subject is asymptomatic  
‚Ä¢ Initiate investigation of alternative causes for elevated AST or ALT and/or elevated 
TBL: 
o Obtain complete blood count (CBC) with differential to assess for eosinophilia  
o Obtain serum total immunoglobulin IgG, Anti -nuclear antibody ( ANA), Anti 
Smooth Muscle Antibody, and Liver Kidney Microsomal antibody 1 ( LKM1 ) to 
assess for autoimmune hepatitis  
o Obtain serum acetaminophen (paracetamol) levels  
o Obtain a more detailed history of:  
‚Ä¢ Prior and/or concurrent diseases or illness 
‚Ä¢ Exposure to environmental and/or industrial chemical agents  
‚Ä¢ Symptoms (if applicable) including right upper quadrant pain, 
hypersensitivity -type reactions, fatigue, nausea, vomiting and fever  
‚Ä¢ Prior and/or concurrent use of alcohol, recreational drugs and special diets  
‚Ä¢ Concomitant use of medications (including non-prescription medicines and 
herbal and dietary supplements), plants, and mushrooms  
o Obtain viral serologies  
o Obtain CPK, haptoglobin, LDH, and peripheral blood smear  
o Perform appropriate liver imaging if clinically i ndicated 
‚Ä¢ Obtain appropriate blood sampling for PK analysis if this has not already been 
collected  
‚Ä¢ Obtain hepatology consult ( liver biopsy may be considered in consultation with an 
hepatologist)  
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  31 March  2016  Page 80 of 84 
CONFIDENTIAL    ‚Ä¢ Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory 
abnormalities return to baseline or normal.  The ‚Äúclose observation period‚Äù is to 
continue for a minimum of [ADDRESS_32647](s) and protocol -required therapi[INVESTIGATOR_014].  
The potential DILI event and additional information such as medical history, concomitant 
medications and laboratory results must be captured in corresponding CRFs. 
 
  Product:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32648]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32649]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32650]:  AMG 334  
Protocol Number:  201 [ZIP_CODE]  
Date:  [ADDRESS_32651]:  AMG 334  
Protocol Number:  20130255  
Date:  31 March 2016  Page 1 of 11 
CONFIDENTIAL    Amendment 3 
Protocol Title:  An Open-label Extension (OLE) Study to Assess the Long-term 
Safety and Efficacy of AMG [ADDRESS_32652] number  2013-005311-27 
 
Amendment Date: 31 March 2016 
 
Rationale:  
This protocol is being  amended to: 
‚Ä¢ clarify language regarding length of time surrounding excluded treatments  
‚Ä¢ align with current protocol template language ( Sections 9 and 12) 
‚Ä¢ update pregnancy and lactation notification worksheets  
‚Ä¢ clarifications made to product complaints section 
‚Ä¢ review of adverse events and serious adverse events added to Open-label 
treatment phase 
‚Ä¢ serious adverse events collection added for Clinical Home Use Substudy  
‚Ä¢ correct typographical, grammatical, and formatting errors throughout the protocol  
 
  Product:  AMG 334  
Protocol Number:  20130255  
Date:  31 March 2016  Page 2 of 11 
CONFIDENTIAL    Description of Changes: 
Section: Global  
Change: Updated version date from 14 October  2015 to 31  March 2016 throughout 
the protocol.  
Section: Global  
Change: Added ‚Äúprefilled‚Äù before all instances of ‚ÄúAI/Pen‚Äù to maintain consistency 
throughout the document. 
Section: Glob al 
Change: Typographical, grammatical, and formatting errors were corrected throughout the protocol.  
Section: Title Page  
Add: 
Amendment 3 31 March 2016 
Section: Protocol Synopsis, [COMPANY_010] Investigational Product Dosage and Administration 
Add: 
Investigational product (IP) (ie, AMG 334 70 mg or 140 mg) will be dosed QM by [CONTACT_33265].  For subjects participating in the CHU substudy, IP is AMG  334 140  mg in 
either a PFS or prefilled AI/Pen. 
Section: Study Glossary  
Add: 
eCRF  Electronic case report form  
ICMJE  International Committee of Medical Journal Editors  
IP Investigational product (ie, AMG  334 or if participating in CHU 
substudy, AMG 334 in either a PFS or prefilled AI/Pen)  
SEC Self-evident corrections  
Section: 6.3 Hepatotoxicity Stoppi[INVESTIGATOR_33219]: 
Subjects with abnormal hepatic laboratory values (ie, alkaline phosphatase [ALP], 
aspartate aminotransferase [AST], alanine aminotransaminase [ALT], total bilirubin [TBL]) and/or international normalized ratio [INR] and/or signs/symptoms of hepatitis (as 
 
  Product:  AMG 334  
Protocol Number:  20130255  
Date:  31 March 2016  Page 3 of 11 
CONFIDENTIAL    described below) may meet the criteria for withholding or permanent discontinuation of 
[COMPANY_010] investigational product or other protocol -required therapi[INVESTIGATOR_33220]-Induced Liver Injury: Premarketing Clinical Evaluation 
(US FDA, 2009). 
Section: [ADDRESS_32653]: 
Throughout the study  and while the subject is receiving investigational product, 
investigators may prescribe any concomitant medications or treatments deemed 
necessary to provide adequate supportive care except for those listed  in Section 6.5. 
With: 
Throughout the study  and while the subject is receiving investigational product, 
investigators may prescribe any concomitant medications or treatments deemed 
necessary to provide adequate supportive care except as noted in Section 6.5. 
Section: 6.[ADDRESS_32654]: 
1. The following medications are excluded throughout the study:  
With: 
1. The following medications are excluded between screening and [ADDRESS_32655] dose of IP : 
Section: 6.5 Excluded Treatments During Study Period, Bullet 2  
Add: 
2. The following medications are excluded only if used daily throughout the month for migraine prophylaxis between screening and [ADDRESS_32656] dose of IP: 
Section: 6.5 Excluded Treatments During Study Period, Bullet 2, Paragraph 2 
Add: 
If the above medications are used daily, but not for migraine prophylaxis, the doses should remain stable between screening and [ADDRESS_32657]:  AMG 334  
Protocol Number:  20130255  
Date:  31 March 2016  Page 4 of 11 
CONFIDENTIAL    Section: 6.[ADDRESS_32658]: 
3. Investigational drugs, devices or procedures (eg, acupuncture, occipi[INVESTIGATOR_33221], transcranial magnetic stimulation) throughout the study. 
With: 
3. Investigational drugs, devices or procedures (eg, acupuncture, occipi[INVESTIGATOR_33192], transcranial magnetic stimulation) between screening and [ADDRESS_32659] dose of IP. 
Section: 6.[ADDRESS_32660] Complaints  
Add: 
This includes any products , devices , or combination products provisioned and/or 
repackaged/modified by [CONTACT_11337].  Product(s) or device(s) includes IP.   
Section: [IP_ADDRESS] Clinical Home Use Substudy (Optional; Limited to Subjects in US, 
[LOCATION_013] and Sweden) , Paragraph 4 
Add: 
Adverse event, serious adverse event, and concomitant medication assessment, vital 
signs measurement, ECGs, urinalysis, and blood draw for serum chemistry and 
hematology analytes and anti -AMG 334 antibody assay will be performed as described 
in the 20130255 study. 
Section: 7.2.4 Open-label Treatment Phase, Day 1 (20130255 week 12 or 40) , Bullet 5  
Add: 
‚Ä¢ Review for ADEs, adverse events, and serious adverse events  
Section: 9.1.1 Definition of Adverse Events , Paragraphs 2 and 3 
Add: 
The definition of adverse events includes worsening of a pre-existing medical condition.  
Worsening indicates that the pre-existing medical condition or underlying disease 
(eg, diabetes, migraine headaches, gout) has increased in severity, frequency, and/or 
duration more than would be expected, and/or has an association with a significantly 
worse outcome th an expected.  A pre -existing condition that has not worsened more 
than anticipated (ie, more than usual fluctuation of disease)  during the study or 
involves an intervention such as elective cosmetic surgery or a medical procedure while 
on study, is not considered an adverse event.   
 
  Product:  AMG 334  
Protocol Number:  20130255  
Date:  [ADDRESS_32661] (ADE) is any adverse event related to the use of a 
medical device.  Adverse device effects include adverse events resulting from insufficient or inadequate instructions for use, adverse events resulting from any 
malfunction of the device, or adverse events resulting from use error or from 
intentional misuse of the device. 
Section: 9.2.1 Reporting Procedures for Adverse Events That do not Meet Serious 
Criteria , Paragraph 2, Bullet 4  
Add: 
‚Ä¢ Assessment of relatedness to investigational product and/or any 
study -mandated activity or procedure, and 
Section: 9.2.1 Reporting Procedures for Adverse Events That do not Meet Serious 
Criteria , Paragraph 7  
Add: 
The investigator must assess whether the adverse event is possibly related to any 
study -mandated activity or procedure (eg, administration of investigational product, 
device(s) [including any screening procedure(s)] ).  This relationship is indicated by a 
‚Äúyes‚Äù or ‚Äúno‚Äù response to the question:  ‚ÄúIs there a reasonable possibility that the event 
may have been caused by a study activity/procedure (eg, administration of 
investigational product, device[s]) ?‚Äù 
Section: 9.[ADDRESS_32662]:  
The pregnancy should be reported to [COMPANY_010]‚Äôs Global Patient Safety within 24 hours of 
the investigator‚Äôs knowledge of the event of a pregnancy.  Report a pregnancy on the Pregnancy Notification Worksheet (Appendix C).  [COMPANY_010]‚Äôs Global Patient Safety will seek to follow the pregnant woman throughout her pregnancy and her baby [CONTACT_8622] 12 months after birth.  
With: 
The pregnancy should be reported to [COMPANY_010]‚Äôs Global Patient Safety within 24 hours of 
the investigator‚Äôs knowledge of the event of a pregnancy.  Report a pregnancy on the 
Pregnancy Notification Works heet (Appendix C).  [COMPANY_010]‚Äôs Global Patient Safety will 
follow -up with the investigator regarding additional information that may be 
requested. 
 
  Product:  AMG 334  
Protocol Number:  20130255  
Date:  31 March 2016  Page 6 of 11 
CONFIDENTIAL    Section: 9.4 Pregnancy and Lactation Reporting, Paragraphs 3 and 4  
Add: 
If a female subject becomes pregnant during the study, the investigator should 
attempt to obtain information regarding the birth outcome and health of the infant.  If a male subject's female partner becomes pregnant, the investigator should discuss obtaining information regarding the birth outcome and health of the infant 
from the pregnant partner. 
If the outcome of the pregnancy meets a criterion for immediate classification as a 
serious adverse event (eg, female subject experiences a spontaneous abortion, stillbirth, neonatal death, or there is a fetal or neonatal congenital anomaly) , the 
investigator will report the event as a serious adverse event. 
Section: 9.4 Pregnancy and Lactation Reporting, Paragraph 6 
Add: 
Any lactation case should be reported to [COMPANY_010]‚Äôs Global Patient Safety within 24 hours 
of the investigator‚Äôs knowledge of event.  Report a lactation case on the Lactation 
Notification Worksheet (Appendix C).  [COMPANY_010] Global Patient Safety will follow -up 
with the investigator regarding additional information that may be requested. 
Section: 12.[ADDRESS_32663]:  
If [COMPANY_010] amends the protocol, agreement from the investigator must be obtained.  
With: 
[COMPANY_010] may amend the protocol  at any time.  After [COMPANY_010] amends the protocol, 
Investigator is to return the signed Investigator‚Äôs Signature [CONTACT_33266]. 
Section: 12.[ADDRESS_32664]:  
Both [COMPANY_010] and the investigator reserve the right to terminate the investigator‚Äôs 
participation in the study according to the study contract.  
With: 
Both [COMPANY_010] and the investigator reserve the right to terminate the investigator‚Äôs 
participation in the study according to the Clinical Trial Agreement . 
 
  Product:  AMG 334  
Protocol Number:  20130255  
Date:  31 March 2016  Page 7 of 11 
CONFIDENTIAL    Section:  12.[ADDRESS_32665]:  
[COMPANY_010] (or designee) will perform self-evident corrections to obvious data errors in the 
clinical trial database, as documented in the Study Specific Self Evident Corrections Plan. 
With: 
[COMPANY_010] (or designee) will perform Self-Evident Corrections (SEC) to obvious data errors 
in the clinical trial database.  SECs will be documented in the eCRF instructions 
available in the EDC system . 
 
Section: 12.[ADDRESS_32666]:  
Authorship of any publications resulting from this study will be determined on the basis 
of the Uniform Requirement for Manuscripts Submitted to Biomedical Journals 
(International Committee of Medical Journal Editors, 2013), which states: 
With: 
Authorship of any publications resulting from this study will be determined on the basis 
of the International Committee of Medical Journal Editors (ICMJE ) 
Recommendations for the Conduct of Reporting, Editing, and Publications of 
Scholarly Work in Medical Journals, which states:  
Section: 13. References  
Add: 
[LOCATION_002] Food Drug Administration. Guidance for Industry Drug-Induced 
Liver Injury: Premarketing Clinical Evaluation.  http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf.  Accessed [ADDRESS_32667]:  AMG 334  
Protocol Number:  20130255  
Date:  31 March 2016  Page 8 of 11 
CONFIDENTIAL    Section:  Appendix C.  Pregnancy Notification Worksheet 
Replace:  
 
 
  Product:  AMG 334  
Protocol Number:  20130255  
Date:  31 March 2016  Page 9 of 11 
CONFIDENTIAL    With: 
 
 
 
  Product:  AMG 334  
Protocol Number:  20130255  
Date:  31 March 2016  Page 10 of 11 
CONFIDENTIAL    Section: Appendix D.  Lactation Notification Worksheet 
Replace:  
 
 
  Product:  AMG 334  
Protocol Number:  20130255  
Date:  31 March 2016  Page 11 of 11 
CONFIDENTIAL    With: 
 
 